OnCo Edge

Proposal: Proposed approval: Aspirin

2026-10-17T00:00:00Z

openFDA has a label for "Aspirin".

17 October 2026, FDA.

On OnCo: Aspirin, Danazol, Givinostat, Ivermectin, Metyrapone, Mifepristone, Nicotinamide, Pancrelipase

Proposal: Proposed new product: Casgevy

2026-10-17T00:00:00Z

EMA register: Casgevy (exagamglogene autotemcel) Authorised, 2024-02-09.

17 October 2026, EMA.

Proposal: Proposed new product: Cystagon

2026-10-17T00:00:00Z

EMA register: Cystagon (mercaptamine bitartrate) Authorised, 1997-06-23.

17 October 2026, EMA.

Proposal: Proposed new product: Entyvio

2026-10-17T00:00:00Z

EMA register: Entyvio (vedolizumab) Authorised, 2014-05-22.

17 October 2026, EMA.

Proposal: Proposed new product: Libmeldy

2026-10-17T00:00:00Z

EMA register: Libmeldy (autologous CD34+ cells encoding ARSA gene) Authorised, 2020-12-17.

17 October 2026, EMA.

Proposal: Proposed new product: Lumeblue

2026-10-17T00:00:00Z

EMA register: Lumeblue (previously Methylthioninium chloride Cosmo) (methylthioninium chloride) Authorised, 2020-08-19.

17 October 2026, EMA.

Proposal: Proposed new product: Lynkuet

2026-10-17T00:00:00Z

EMA register: Lynkuet (elinzanetant) Authorised, 2025-11-17.

17 October 2026, EMA.

Proposal: Proposed new product: NeoRecormon

2026-10-17T00:00:00Z

EMA register: NeoRecormon (epoetin beta) Authorised, 1997-07-16.

17 October 2026, EMA.

Proposal: Proposed new product: Nezglyal

2026-10-17T00:00:00Z

EMA register: Nezglyal (leriglitazone) Authorised, 2026-09-21.

17 October 2026, EMA.

Proposal: Proposed new product: Procysbi

2026-10-17T00:00:00Z

EMA register: Procysbi (mercaptamine) Authorised, 2013-09-05.

17 October 2026, EMA.

Proposal: Proposed new product: SomaKit TOC

2026-10-17T00:00:00Z

EMA register: SomaKit TOC (edotreotide) Authorised, 2016-12-08.

17 October 2026, EMA.

Proposal: Proposed new product: Strimvelis

2026-10-17T00:00:00Z

EMA register: Strimvelis (autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) Authorised, 2016-05-26.

17 October 2026, EMA.

Proposal: Proposed new product: Waskyra

2026-10-17T00:00:00Z

EMA register: Waskyra (etuvetidigene autotemcel) Authorised, 2026-01-09.

17 October 2026, EMA.

Proposal: Proposed new product: Xromi

2026-10-17T00:00:00Z

EMA register: Xromi (hydroxycarbamide) Authorised, 2019-07-01.

17 October 2026, EMA.

Proposal: Proposed new product: Yartemlea

2026-10-17T00:00:00Z

EMA register: Yartemlea (Narsoplimab) Opinion under re-examination.

17 October 2026, EMA.

Proposal: Proposed new product: Zefylti

2026-10-17T00:00:00Z

EMA register: Zefylti (filgrastim) Application withdrawn.

17 October 2026, EMA.

Proposal: Proposed trial status change: A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

2026-10-17T00:00:00Z

ClinicalTrials.gov overall status is TERMINATED; recorded recruiting.

17 October 2026, ClinicalTrials.gov.

On OnCo: A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Proposal: Proposed trial status change: A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inopera

2026-10-17T00:00:00Z

ClinicalTrials.gov overall status is RECRUITING; recorded planned.

17 October 2026, ClinicalTrials.gov.

On OnCo: A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inopera

Proposal: Proposed trial status change: A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

2026-10-17T00:00:00Z

ClinicalTrials.gov overall status is RECRUITING; recorded planned.

17 October 2026, ClinicalTrials.gov.

On OnCo: A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

Proposal: Proposed trial status change: A Study of PTX-9908 Injection for Non-resectable HCC with TACE

2026-10-17T00:00:00Z

ClinicalTrials.gov overall status is WITHDRAWN; recorded recruiting.

17 October 2026, ClinicalTrials.gov.

On OnCo: A Study of PTX-9908 Injection for Non-resectable HCC with TACE

Issue: OnCo weekly, 2026-10-16

2026-10-16T00:00:00Z

1000 changelog entries, 1 upcoming date, 3 corrections.

16 October 2026, OnCo weekly issue.

Approval: FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma

2026-10-02T00:00:00Z

On October 2, 2026, the Food and Drug Administration approved pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.

2 October 2026, FDA.

On OnCo: Pirtobrutinib, Non-Hodgkin lymphoma, Adult T-cell leukaemia/lymphoma, Leukaemia

Paper: Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum.

2026-10-08T00:00:00Z

Published in Nat Rev Clin Oncol on 8 October 2026; matched the OnCo record for Trastuzumab deruxtecan.

8 October 2026, Nat Rev Clin Oncol.

On OnCo: Trastuzumab deruxtecan

Issue: OnCo weekly, 2026-10-14

2026-10-14T00:00:00Z

993 changelog entries, 1 upcoming date, 3 corrections.

14 October 2026, OnCo weekly issue.

Issue: OnCo weekly, 2026-10-12

2026-10-12T00:00:00Z

982 changelog entries, 1 upcoming date, 33 corrections.

12 October 2026, OnCo weekly issue.

Issue: OnCo weekly, 2026-10-09

2026-10-09T00:00:00Z

969 changelog entries, 1 upcoming date, 30 corrections.

9 October 2026, OnCo weekly issue.

Issue: OnCo weekly, 2026-10-08

2026-10-08T00:00:00Z

950 changelog entries, 1 upcoming date, 30 corrections.

8 October 2026, OnCo weekly issue.

Paper: Benefit from perioperative enfortumab vedotin-pembrolizumab in cisplatin-eligible MIBC.

2026-10-01T00:00:00Z

Published in Nat Rev Clin Oncol on 1 October 2026; matched the OnCo record for Enfortumab vedotin.

1 October 2026, Nat Rev Clin Oncol.

On OnCo: Enfortumab vedotin

Paper: HCT-ASCT confirmed as standard-of-care consolidation therapy for PCNSL.

2026-10-01T00:00:00Z

Published in Nat Rev Clin Oncol on 1 October 2026; matched the OnCo record for Primary CNS lymphoma.

1 October 2026, Nat Rev Clin Oncol.

On OnCo: Primary CNS lymphoma

Approval: FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component

2026-09-24T00:00:00Z

On September 24, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.

24 September 2026, FDA.

On OnCo: Lenvatinib, Belzutifan, Renal cell carcinoma, Clear cell renal cell carcinoma, Spinal cord tumours, Pancreatic neuroendocrine tumours, Hereditary pheochromocytoma and paraganglioma, Hepatocellular carcinoma, Advanced hepatocellular carcinoma, Intermediate hepatocellular carcinoma, Thyroid cancer

Issue: OnCo weekly, 2026-10-07

2026-10-07T00:00:00Z

898 changelog entries, 1 upcoming date, 26 corrections.

7 October 2026, OnCo weekly issue.

Approval: FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma

2026-09-23T00:00:00Z

On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.

23 September 2026, FDA.

On OnCo: Lirafugratinib, Biliary tract cancer, FGFR2

Preprint: A tuneable structural switch controls RNF213 activity and is bypassed in Moyamoya disease

2026-10-11T00:00:00Z

Posted on medRxiv on 11 October 2026; not peer reviewed; matched RNF213.

11 October 2026, medRxiv.

On OnCo: RNF213

Preprint: Carotid Body Paraganglioma Presenting With Paroxysmal Hypertension: A Case Report

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched CCDC6.

11 October 2026, Research Square.

On OnCo: CCDC6

Preprint: CD19 CAR Engineered T Regulatory Cells Promote Durable Immune Tolerance in Experimental Systemic Lupus Erythematosus

2026-10-11T00:00:00Z

Posted on bioRxiv on 11 October 2026; not peer reviewed; matched CAR-T cell therapy.

11 October 2026, bioRxiv.

On OnCo: CAR-T cell therapy

Preprint: Collapsing Focal Segmental Glomerulosclerosis Progression to ESRD Following Combination Therapy with Pembrolizumab and Enfortumab Vedotin: A Case Report

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched Cisplatin, Rituximab and Platinum agents.

11 October 2026, Research Square.

On OnCo: Cisplatin, Rituximab, Platinum agents, Antibody-drug conjugate, Immune checkpoint inhibitors, EGFR

Preprint: Differential Immune Dynamics in Large B-Cell Lymphoma Patients Treated With Axi-Cel and Tisa-Cel Car-T Cell Products

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched Tisagenlecleucel, CAR-T cell therapy and CD19.

11 October 2026, Research Square.

On OnCo: Tisagenlecleucel, CAR-T cell therapy, CD19, Axicabtagene ciloleucel

Preprint: Early Prediction of Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma Using a Three-Gene Classifier

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched BIRC5 and HNRNPA2B1.

11 October 2026, Research Square.

On OnCo: BIRC5, HNRNPA2B1

Preprint: Early-Onset Rectal Adenocarcinoma as the Initial Manifestation of Li- Fraumeni Syndrome Associated with a Germline TP53 p.R337H Variant: A Case Report and Literature Review

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched Whole-exome & whole-genome sequencing, Germline (hereditary) testing and TP53.

11 October 2026, Research Square.

On OnCo: Whole-exome & whole-genome sequencing, Germline (hereditary) testing, TP53

Preprint: EGFR tyrosine kinase inhibitor receipt and overall survival in metastatic non-small cell lung cancer in Egypt A retrospective descriptive cohort study

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched Small-molecule kinase inhibitors, EGFR and Erlotinib.

11 October 2026, Research Square.

On OnCo: Small-molecule kinase inhibitors, EGFR, Erlotinib, Gefitinib, EGF

Preprint: Genome-based benchmarking of 177 different breast cancer polygenic risk scores

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched HER2 and SET.

11 October 2026, Research Square.

On OnCo: HER2, SET

Preprint: Harmine derivative ACB1801 induces ferroptosis vulnerability and STAT1 pathway activation to sensitize MSS colorectal cancer to anti–PD-1 immunotherapy

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched PD-1, State and STAT1.

11 October 2026, Research Square.

On OnCo: PD-1, State, STAT1, CXCL10

Preprint: Hospital financial implications of subcutaneous versus intravenous trastuzumab plus pertuzumab in Japan: a micro-costing and threshold analysis

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched Pertuzumab and Trastuzumab.

11 October 2026, Research Square.

On OnCo: Pertuzumab, Trastuzumab

Preprint: How to improve cancer outreach programmes in rural areas: insights from a realist evaluation

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched Chemoprevention & risk-reducing surgery.

11 October 2026, Research Square.

On OnCo: Chemoprevention & risk-reducing surgery

Preprint: Inferring ecDNA Evolution from Allele Frequency Spectra

2026-10-11T00:00:00Z

Posted on bioRxiv on 11 October 2026; not peer reviewed; matched Whole-exome & whole-genome sequencing.

11 October 2026, bioRxiv.

On OnCo: Whole-exome & whole-genome sequencing

Preprint: Integrated Single-Cell and Cross-Species Analysis Reveals CMP Vulnerability and SMYD3 as a Novel Epigenetic Biomarker in Acute Myeloid Leukemia

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and EZH2.

11 October 2026, Research Square.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling, EZH2, NRAS, ETV6

Preprint: Integrative Omics Analysis Reveals Functional Variants of Hemoglobin Zeta (HBZ) as an Ancestry-Specific Risk Factor for Triple-Negative Breast Cancer

2026-10-11T00:00:00Z

Posted on medRxiv on 11 October 2026; not peer reviewed; matched Whole-exome & whole-genome sequencing, CCDC6 and NR4A3.

11 October 2026, medRxiv.

On OnCo: Whole-exome & whole-genome sequencing, CCDC6, NR4A3

Preprint: Linking somatic variants to altered methylation profiles in nanopore-derived breast and pancreatic cancer genomes using unduliner

2026-10-11T00:00:00Z

Posted on bioRxiv on 11 October 2026; not peer reviewed; matched DNA methylation profiling.

11 October 2026, bioRxiv.

On OnCo: DNA methylation profiling

Preprint: MESNet: A Lightweight Transformer-CNN Collaborative Network with Morphology Awareness for Glioma Segmentation

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched State.

11 October 2026, Research Square.

On OnCo: State

Preprint: Microglia transcriptomic response to doxorubicin-induced genotoxic stress

2026-10-11T00:00:00Z

Posted on bioRxiv on 11 October 2026; not peer reviewed; matched Doxorubicin.

11 October 2026, bioRxiv.

On OnCo: Doxorubicin

Preprint: Patient-derived organoids inform treatment response and clinical outcomes in tumors of uncertain differentiation

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched Patient-derived organoids and Immune checkpoint inhibitors.

11 October 2026, Research Square.

On OnCo: Patient-derived organoids, Immune checkpoint inhibitors

Preprint: Plasma exosomal miR-29b promotes the progression of endometrial cancer by activating the Wnt/β-catenin signaling pathway via FOLR1-mediated regulation of CTNNB1

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched Liquid biopsy, Folate receptor alpha and CTNNB1.

11 October 2026, Research Square.

On OnCo: Liquid biopsy, Folate receptor alpha, CTNNB1

Preprint: Posterior reversible encephalopathy syndrome during enfortumab vedotin therapy: a case report

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched MRI, Antibody-drug conjugate and Enfortumab vedotin.

11 October 2026, Research Square.

On OnCo: MRI, Antibody-drug conjugate, Enfortumab vedotin, Nivolumab

Preprint: Primary Leiomyosarcoma of the Urinary Bladder in a Middle-Aged Woman: A Case Report with Review of Previously Published Cases

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched MYOD1 and SOX10.

11 October 2026, Research Square.

On OnCo: MYOD1, SOX10

Preprint: Psilocybin-Assisted Therapy for Existential Distress in Serious and Life-Limiting Illness: Emerging Trial Evidence, Barriers to Access, and the Case for Individualized Eligibility

2026-10-11T00:00:00Z

Posted on PsyArXiv on 11 October 2026; not peer reviewed; matched State.

11 October 2026, PsyArXiv.

On OnCo: State

Preprint: QSOX1 Promotes Migration and Invasion in Epithelial Ovarian Cancer Cells with Functional Involvement of CLDN1

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched RNA sequencing & expression profiling.

11 October 2026, Research Square.

On OnCo: RNA sequencing & expression profiling

Preprint: Radiation-Induced High-Grade Glioma in a Long-Term Survivor of Medulloblastoma: A Case Report

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched MRI, IDH1 / IDH2 and Ki-67.

11 October 2026, Research Square.

On OnCo: MRI, IDH1 / IDH2, Ki-67, ATRX

Preprint: Salivary microbiome exhibits stage-associated network topological shifts in upper gastrointestinal carcinogenesis

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched Azacitidine, Decitabine + cedazuridine and CLTC.

11 October 2026, Research Square.

On OnCo: Azacitidine, Decitabine + cedazuridine, CLTC

Preprint: Scalable methylome-transcriptome profiling resolves clonal organization in human hematopoiesis

2026-10-11T00:00:00Z

Posted on bioRxiv on 11 October 2026; not peer reviewed; matched Single-cell & spatial profiling and State.

11 October 2026, bioRxiv.

On OnCo: Single-cell & spatial profiling, State

Preprint: Six-Weekly Low-Dose Nivolumab Combined with Oral Triple Metronomic Chemotherapy for Advanced Cancers of the Head and Neck: An Open-Label, Prospective, Single-Institution Experience from Eastern India

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched Cisplatin, Azacitidine and Decitabine + cedazuridine.

11 October 2026, Research Square.

On OnCo: Cisplatin, Azacitidine, Decitabine + cedazuridine, Cytotoxic chemotherapy, Platinum agents, Pembrolizumab

Preprint: SORT disentangles multilevel gene programs across heterogeneous spatial transcriptomic atlases

2026-10-11T00:00:00Z

Posted on bioRxiv on 11 October 2026; not peer reviewed; matched Atlas.

11 October 2026, bioRxiv.

On OnCo: Atlas

Preprint: Thrombotic Risk of Targeted Therapies in Breast Cancer: A Real-World Cohort Study

2026-10-11T00:00:00Z

Posted on Research Square on 11 October 2026; not peer reviewed; matched Everolimus, CDK4/6 inhibitors and CDK4/6.

11 October 2026, Research Square.

On OnCo: Everolimus, CDK4/6 inhibitors, CDK4/6, PARP, Palbociclib, mTOR

Preprint: Tissue retention of dendritic cells drives age-associated protective tolerogenic lymphoid structures

2026-10-11T00:00:00Z

Posted on bioRxiv on 11 October 2026; not peer reviewed; matched State.

11 October 2026, bioRxiv.

On OnCo: State

Preprint: Point-Process Modelling of Cell-Type Interaction Structure in CosMx Glioma Data for Hypothesis-Driven Tumor Inference from scRNA-seq

2026-10-10T00:00:00Z

Posted on bioRxiv on 10 October 2026; not peer reviewed; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and Nicheformer.

10 October 2026, bioRxiv.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling, Nicheformer

Preprint: Repurposing clofarabine against enteric pathogens via metabolic starvation

2026-10-10T00:00:00Z

Posted on bioRxiv on 10 October 2026; not peer reviewed; matched Clofarabine.

10 October 2026, bioRxiv.

On OnCo: Clofarabine

Preprint: Restoration of deficient IL-15 signaling enhances innate lymphoid cell immunity in brain metastasis

2026-10-10T00:00:00Z

Posted on bioRxiv on 10 October 2026; not peer reviewed; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and TNFRSF10B.

10 October 2026, bioRxiv.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling, TNFRSF10B

Paper: Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.

2026-10-03T00:00:00Z

Published in Urol Oncol on 3 October 2026; found by the roadmap watch for A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy.

3 October 2026, Urol Oncol.

On OnCo: A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch

Paper: Germinoma in late adulthood with extensive dissemination: a case report and literature review.

2026-10-03T00:00:00Z

Published on 3 October 2026 after first appearing as a preprint; matched MRI, DNA methylation profiling and Platinum agents.

3 October 2026.

On OnCo: MRI, DNA methylation profiling, Platinum agents, Carboplatin, Etoposide

Paper: How community pharmacies can raise uterine cancer awareness among women from ethnic minority populations.

2026-10-03T00:00:00Z

Published on 3 October 2026 after first appearing as a preprint; matched CCDC6.

3 October 2026.

On OnCo: CCDC6

Paper: Serum albumin is associated with immune-related hypothyroidism and treatment continuity in non-small cell lung cancer.

2026-10-03T00:00:00Z

Published on 3 October 2026 after first appearing as a preprint; matched Nintedanib, Immune checkpoint inhibitors and CCDC6.

3 October 2026.

On OnCo: Nintedanib, Immune checkpoint inhibitors, CCDC6

Paper: Stacked Waves and Qualitative Analysis of an Oncolytic Virus-Immune Model.

2026-10-03T00:00:00Z

Published on 3 October 2026 after first appearing as a preprint; matched Oncolytic viruses and Mathematical models of cancer.

3 October 2026.

On OnCo: Oncolytic viruses, Mathematical models of cancer

Preprint: A generalized similarity metric based on Sobolev space geometry for deformable image registration in image-guided radiotherapy

2026-10-09T00:00:00Z

Posted on Research Square on 9 October 2026; not peer reviewed; matched IMRT / IGRT, MR-guided adaptive radiotherapy and Adaptive radiotherapy.

9 October 2026, Research Square.

On OnCo: IMRT / IGRT, MR-guided adaptive radiotherapy, Adaptive radiotherapy

Preprint: A novel HDAC6/HIF-1α dual inhibitor halts malignant progression and reprograms immune microenvironment in triple-negative breast cancer

2026-10-09T00:00:00Z

Posted on Research Square on 9 October 2026; not peer reviewed; matched Sorafenib, Anti-angiogenic therapy and Panobinostat.

9 October 2026, Research Square.

On OnCo: Sorafenib, Anti-angiogenic therapy, Panobinostat, Histone deacetylases, HIF-1α

Preprint: A spatial AI-based biomarker with independent prognostic value in early low- and intermediate- risk breast cancer

2026-10-09T00:00:00Z

Posted on medRxiv on 9 October 2026; not peer reviewed; matched HER2, CCDC6 and SET.

9 October 2026, medRxiv.

On OnCo: HER2, CCDC6, SET

Preprint: An Immunocompetent Mouse Model of Degarelix Induced Chemical Castration to Investigate Acquired Resistance to Androgen Deprivation.

2026-10-09T00:00:00Z

Posted on bioRxiv on 9 October 2026; not peer reviewed; matched Degarelix and ELL.

9 October 2026, bioRxiv.

On OnCo: Degarelix, ELL

Preprint: Artificial Intelligence Applied to Epigenomic Data in Leukemia: A Systematic Review of Diagnostic, Prognostic and Monitoring Models

2026-10-09T00:00:00Z

Posted on bioRxiv on 9 October 2026; not peer reviewed; matched DNA methylation profiling and CCDC6.

9 October 2026, bioRxiv.

On OnCo: DNA methylation profiling, CCDC6

Preprint: Auditable Federated Learning for Multimodal Brain Tumor Classification under Label Skew and Client Dropout

2026-10-09T00:00:00Z

Posted on Research Square on 9 October 2026; not peer reviewed; matched MRI and SET.

9 October 2026, Research Square.

On OnCo: MRI, SET

Paper: Frequency and Prognostic Significance of T-wave Inversions in Athletes: A Systematic Review and Meta-analysis.

2026-10-02T00:00:00Z

Published on 2 October 2026 after first appearing as a preprint; matched CCDC6.

2 October 2026.

On OnCo: CCDC6

Paper: Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies.

2026-10-02T00:00:00Z

Published on 2 October 2026 after first appearing as a preprint; matched Pertuzumab, RNA sequencing & expression profiling and Single-cell & spatial profiling.

2 October 2026.

On OnCo: Pertuzumab, RNA sequencing & expression profiling, Single-cell & spatial profiling, Pembrolizumab, Ipilimumab

Paper: Patient preferences for treatment‑free intervals in multiple myeloma: mixed‑methods insights on monitoring trade‑offs and supportive care improvements.

2026-10-02T00:00:00Z

Published on 2 October 2026 after first appearing as a preprint; matched CCDC6.

2 October 2026.

On OnCo: CCDC6

Paper: The landscape of allele-specific expression in human kidneys.

2026-10-02T00:00:00Z

Published on 2 October 2026 after first appearing as a preprint; matched Whole-exome & whole-genome sequencing and RNA sequencing & expression profiling.

2 October 2026.

On OnCo: Whole-exome & whole-genome sequencing, RNA sequencing & expression profiling

Paper: Tumor cell-intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer.

2026-10-02T00:00:00Z

Published on 2 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling, CAR-T cell therapy and State.

2 October 2026.

On OnCo: Single-cell & spatial profiling, CAR-T cell therapy, State, NFE2L2, KEAP1

Paper: Erratum: Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial.

2026-09-25T00:00:00Z

Published in J Clin Oncol on 25 September 2026; found by the roadmap watch for STELLAR.

25 September 2026, J Clin Oncol.

On OnCo: STELLAR, Devices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implants

Approval: FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

2026-09-18T00:00:00Z

On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.

18 September 2026, FDA.

On OnCo: Imlunestrant, Abemaciclib, HR-positive / HER2-negative breast cancer, Breast cancer, High-risk early HR-positive breast cancer, HR-positive metastatic breast cancer after CDK4/6 inhibitors, CDK4/6, Estrogen receptor

Paper: [Clues for identifying Diamond-Blackfan anemia among infants with early severe anemia: Clinical and genetic analysis of 11 cases].

2026-10-01T00:00:00Z

Published in Zhonghua Yi Xue Yi Chuan Xue Za Zhi on 1 October 2026; matched the OnCo record for RPS19.

1 October 2026, Zhonghua Yi Xue Yi Chuan Xue Za Zhi.

On OnCo: RPS19, RPS29

Paper: A Deep-Learning Based Biomarker of Systemic Cellular Senescence Burden to Predict Mortality and Health Outcomes.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics.

1 October 2026.

On OnCo: Proteomics & phosphoproteomics

Paper: A high-throughput method to computationally develop candidate adverse outcome pathways in humans: a proof of concept with insecticides and Parkinson's Disease.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched Atlas, PTEN and MAPK1.

1 October 2026.

On OnCo: Atlas, PTEN, MAPK1

Paper: Adolescent health across Asia Pacific, 2000-23: a systematic analysis for the Global Burden of Disease Study 2023.

2026-10-01T00:00:00Z

Published in Lancet Child Adolesc Health on 1 October 2026; matched the OnCo record for Logic-gated therapeutics.

1 October 2026, Lancet Child Adolesc Health.

On OnCo: Logic-gated therapeutics

Paper: Analysis of end-stage renal disease mediated by cuproptosis-related genes.

2026-10-01T00:00:00Z

Published in Clin Nephrol on 1 October 2026; matched the OnCo record for ATP7B.

1 October 2026, Clin Nephrol.

On OnCo: ATP7B, DLST

Paper: Approaches to thyroid nodules in paediatric cancer predisposition syndromes.

2026-10-01T00:00:00Z

Published in Eur Thyroid J on 1 October 2026; matched the OnCo record for DICER1.

1 October 2026, Eur Thyroid J.

On OnCo: DICER1

Paper: ASO Visual Abstract: A Prospective Multicenter Comparative Cohort Study of Neoadjuvant Sintilimab Plus Chemotherapy and Chemoradiotherapy in Resectable Clinical Node-Positive Esophageal Squamous Cell Carcinoma.

2026-10-01T00:00:00Z

Published in Ann Surg Oncol on 1 October 2026; matched the OnCo record for Sintilimab.

1 October 2026, Ann Surg Oncol.

On OnCo: Sintilimab

Paper: ASO Visual Abstract: Mex3a Stabilizes INHBB mRNA to Activate SMAD-Signaling and Promote Hepatocellular Carcinoma Metastasis.

2026-10-01T00:00:00Z

Published in Ann Surg Oncol on 1 October 2026; matched the OnCo record for INHBB.

1 October 2026, Ann Surg Oncol.

On OnCo: INHBB

Paper: ASO Visual Abstract: Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer.

2026-10-01T00:00:00Z

Published in Ann Surg Oncol on 1 October 2026; matched the OnCo record for Claudin 18.2.

1 October 2026, Ann Surg Oncol.

On OnCo: Claudin 18.2

Paper: ASO Visual Abstract: Treatment for Oligo-recurrence of Diffuse Pleural Mesothelioma After Extended Pleurectomy/Decortication.

2026-10-01T00:00:00Z

Published in Ann Surg Oncol on 1 October 2026; matched the OnCo record for Pleural mesothelioma.

1 October 2026, Ann Surg Oncol.

On OnCo: Pleural mesothelioma

Paper: Association Between Danish Guideline Treatments for Breast Cancer and Physiotherapy-Relevant Late Effects: A Nationwide Cohort Study.

2026-10-01T00:00:00Z

Published in Physiother Res Int on 1 October 2026; matched the OnCo record for Sentinel lymph node biopsy.

1 October 2026, Physiother Res Int.

On OnCo: Sentinel lymph node biopsy

Paper: ATG exposure in T replete transplant for hematological malignancies: Real world analysis from BMT CTN 1202.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched Rebuilding the immune system after treatment and Chronic graft-versus-host disease.

1 October 2026.

On OnCo: Rebuilding the immune system after treatment, Chronic graft-versus-host disease

Paper: ATP Release and Purinergic Signaling Potentiate β-Adrenergic Effects on Brown Adipocytes.

2026-10-01T00:00:00Z

Published in Acta Physiol (Oxf) on 1 October 2026; matched the OnCo record for MPEG1.

1 October 2026, Acta Physiol (Oxf).

On OnCo: MPEG1

Paper: Biological effects of N-acetylcysteine, calcium hydroxide, chlorhexidine and their combinations as intracanal medications: cytotoxicity, genotoxicity and cytokine modulation.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched CCDC6 and Interleukin-10.

1 October 2026.

On OnCo: CCDC6, Interleukin-10

Paper: Blinatumomab-induced catastrophic immune effector cell-associated neurotoxicity with diffuse cerebral edema in a patient with ALL: Case report.

2026-10-01T00:00:00Z

Published in Int J Clin Pharmacol Ther on 1 October 2026; matched the OnCo record for AFF1.

1 October 2026, Int J Clin Pharmacol Ther.

On OnCo: AFF1, Blinatumomab

Paper: Cell Type-Specific Roles of TBK1 in Steatotic Liver Disease: Evidence for an Inflammatory TBK1+CASP1+ Kupffer Cell State.

2026-10-01T00:00:00Z

Published in Liver Int on 1 October 2026; matched the OnCo record for TBK1.

1 October 2026, Liver Int.

On OnCo: TBK1

Paper: Characterizing intra- and intertumor heterogeneity in ovarian high-grade serous carcinoma subtypes using single-cell and spatial transcriptomics.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and Spatial transcriptomics.

1 October 2026.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling, Spatial transcriptomics

Paper: CodeMergeR: A Shiny-Based Application for Codelist Integration.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched CCDC6.

1 October 2026.

On OnCo: CCDC6

Paper: Commissioning and end-to-end validation of a combined surface-guided and triggered kV imaging workflow for breath-hold SBRT on a Varian TrueBeam.

2026-10-01T00:00:00Z

Published in J Appl Clin Med Phys on 1 October 2026; matched the OnCo record for In-room imaging for radiotherapy.

1 October 2026, J Appl Clin Med Phys.

On OnCo: In-room imaging for radiotherapy

Paper: Conformational stability and domain-specific structural features of tumor autoantigens regulate autoantibody epitope propensity.

2026-10-01T00:00:00Z

Published in Protein Sci on 1 October 2026; matched the OnCo record for CTAG1B.

1 October 2026, Protein Sci.

On OnCo: CTAG1B, WT1

Paper: Correction to 'FOLFOX Versus FOLFIRI as Second-Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study'.

2026-10-01T00:00:00Z

Published in Liver Int on 1 October 2026; matched the OnCo record for FOLFIRI.

1 October 2026, Liver Int.

On OnCo: FOLFIRI, FOLFOX

Paper: Cross-Talk Between Histamine H2 Receptor and Glucocorticoid Receptor: Potential Implications in Acute Myeloid Leukemia Treatment.

2026-10-01T00:00:00Z

Published in Pharmacol Res Perspect on 1 October 2026; matched the OnCo record for Cytarabine.

1 October 2026, Pharmacol Res Perspect.

On OnCo: Cytarabine

Paper: CX3CR1 Modulates Migration of Resident Microglia Towards Cortical Laser-Induced Lesions.

2026-10-01T00:00:00Z

Published in Glia on 1 October 2026; matched the OnCo record for CX3CL1.

1 October 2026, Glia.

On OnCo: CX3CL1

Paper: Diet-Induced Phospholipid Remodeling Dictates Ferroptosis Sensitivity and Tumorigenesis in the Pancreas.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched KRAS.

1 October 2026.

On OnCo: KRAS

Paper: Distant lymph nodes compensate for resected tumor-draining lymph nodes during cancer immunotherapy.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched Immune checkpoint inhibitors and PD-1.

1 October 2026.

On OnCo: Immune checkpoint inhibitors, PD-1

Paper: Effectiveness of green health prescribing and nature-based interventions in primary care and community settings for older adults: a systematic review of health, wellbeing and social outcomes.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched CCDC6.

1 October 2026.

On OnCo: CCDC6

Paper: Effects of curcumin and nicorandil on nilotinib-induced QT interval prolongation in rats: A telemetry-based study.

2026-10-01T00:00:00Z

Published in Pak J Pharm Sci on 1 October 2026; matched the OnCo record for Nilotinib.

1 October 2026, Pak J Pharm Sci.

On OnCo: Nilotinib

Paper: Effects of Progressive Inspiratory Muscle Training on Lung Volume and Respiratory Strength in Patients With Pre-Dialysis Chronic Kidney Disease.

2026-10-01T00:00:00Z

Published in Physiother Res Int on 1 October 2026; matched the OnCo record for Inflammatory myofibroblastic tumour.

1 October 2026, Physiother Res Int.

On OnCo: Inflammatory myofibroblastic tumour

Paper: Elevated Expression of Caveolin-1 Reflects a Poor Prognosis in Patients With Primary Central Nervous System Lymphomas.

2026-10-01T00:00:00Z

Published in Neuropathology on 1 October 2026; matched the OnCo record for Primary CNS lymphoma.

1 October 2026, Neuropathology.

On OnCo: Primary CNS lymphoma

Paper: End-to-End PET/CT Interpretation and Quantification with an LLM-Orchestrated AI Agent: A Real-World Pilot Study.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched PET/CT, FDG PET and AI trial matching & clinical decision support.

1 October 2026.

On OnCo: PET/CT, FDG PET, AI trial matching & clinical decision support, Fludeoxyglucose F-18

Paper: Engineering a protein homodimer from a heterodimer: A chimeric DBHS protein.

2026-10-01T00:00:00Z

Published in Protein Sci on 1 October 2026; matched the OnCo record for PSPC1.

1 October 2026, Protein Sci.

On OnCo: PSPC1, SFPQ

Paper: Estradiol Promotes Tumor Progression in ERα-Low Endometrial Cancer via the GPER/SphK1 Pathway.

2026-10-01T00:00:00Z

Published in J Biochem Mol Toxicol on 1 October 2026; matched the OnCo record for CCNE1.

1 October 2026, J Biochem Mol Toxicol.

On OnCo: CCNE1, SPHK1

Paper: Evaluation of interfractional shift corrections in Gamma Knife radiosurgery.

2026-10-01T00:00:00Z

Published in J Appl Clin Med Phys on 1 October 2026; matched the OnCo record for Gamma Knife.

1 October 2026, J Appl Clin Med Phys.

On OnCo: Gamma Knife

Paper: External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.

2026-10-01T00:00:00Z

Published in Cancer on 1 October 2026; found by the roadmap watch for ARCHES.

1 October 2026, Cancer.

On OnCo: ARCHES, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test

Paper: Factors influencing access to green health prescribing in primary care for older adults - a qualitative systematic review.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched Med-Gemini and MedLM and CCDC6.

1 October 2026.

On OnCo: Med-Gemini and MedLM, CCDC6

Paper: Feasibility of lattice radiation therapy using a noncoplanar vertex arrangement and dynamic conformal arcs.

2026-10-01T00:00:00Z

Published in J Appl Clin Med Phys on 1 October 2026; matched the OnCo record for VDR.

1 October 2026, J Appl Clin Med Phys.

On OnCo: VDR

Paper: Fertility-Sparing Treatment of Endometrial Cancer: Survey of Australian Practice.

2026-10-01T00:00:00Z

Published in Aust N Z J Obstet Gynaecol on 1 October 2026; matched the OnCo record for Progestins.

1 October 2026, Aust N Z J Obstet Gynaecol.

On OnCo: Progestins, POLE

Paper: FOCS-24: An integrated oncologic-functional endpoint and its preoperative nomogram after focal therapy for localized prostate cancer.

2026-10-01T00:00:00Z

Published in Urol Oncol on 1 October 2026; matched the OnCo record for Multiparametric prostate MRI.

1 October 2026, Urol Oncol.

On OnCo: Multiparametric prostate MRI

Paper: Fruquintinib: Mechanism of Action, Clinical, and Translational Science.

2026-10-01T00:00:00Z

Published in Clin Transl Sci on 1 October 2026; matched the OnCo record for Fruquintinib.

1 October 2026, Clin Transl Sci.

On OnCo: Fruquintinib

Paper: Furin inhibition protects against acute lung injury in a mouse model of Pseudomonas aeruginosa infection.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling and TNFRSF10B.

1 October 2026.

On OnCo: RNA sequencing & expression profiling, TNFRSF10B

Paper: Gender-Specific Cancer-Related Survival Analysis of Robotic Versus Laparoscopic Low Anterior Resection for Rectal Adenocarcinoma: A Multicenter Study.

2026-10-01T00:00:00Z

Published in Int J Med Robot on 1 October 2026; matched the OnCo record for Luminal androgen receptor triple-negative breast cancer.

1 October 2026, Int J Med Robot.

On OnCo: Luminal androgen receptor triple-negative breast cancer

Paper: Ginsenosides Rb1 and Rg1 Suppress Lipopolysaccharide-Induced Inflammatory Gene Expression in Microglia and Astrocytes, Unlike Rb2.

2026-10-01T00:00:00Z

Published in Pharmacol Res Perspect on 1 October 2026; matched the OnCo record for RB1.

1 October 2026, Pharmacol Res Perspect.

On OnCo: RB1

Paper: Gut Microbiome Diversity, Functional Potential, and Ecological Relevance of Hottentotta tamulus.

2026-10-01T00:00:00Z

Published in Microbiologyopen on 1 October 2026; matched the OnCo record for MT-CO1.

1 October 2026, Microbiologyopen.

On OnCo: MT-CO1

Paper: HDAC Inhibition Unlocks Tumor Plasticity and Enhances Immunotherapy Response in Myc-Driven Small Cell Lung Cancer.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched PD-1, Histone deacetylases and HDAC4.

1 October 2026.

On OnCo: PD-1, Histone deacetylases, HDAC4, RB1, MYC

Paper: Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis: Clinical Presentation and Outcomes in Three Patients.

2026-10-01T00:00:00Z

Published in J Immunother on 1 October 2026; matched the OnCo record for Tocilizumab.

1 October 2026, J Immunother.

On OnCo: Tocilizumab

Paper: Impact of post-chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children's Oncology Group AREN0532, AREN0533, and AREN03B2 studies.

2026-10-01T00:00:00Z

Published in Cancer on 1 October 2026; matched the OnCo record for Advanced-stage classical Hodgkin lymphoma.

1 October 2026, Cancer.

On OnCo: Advanced-stage classical Hodgkin lymphoma

Paper: Inhibition of Acetylation Activity of p300/CBP Ameliorates Hepatic Steatosis Through Downregulation of ACSL4.

2026-10-01T00:00:00Z

Published in Liver Int on 1 October 2026; matched the OnCo record for EP300.

1 October 2026, Liver Int.

On OnCo: EP300

Paper: Inhibition of Hexokinase 2 Undermines Cartilage Health and Accelerates Osteoarthritis.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and COL2A1.

1 October 2026.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling, COL2A1

Paper: Insulin autoimmune syndrome (Hirata Disease): An updated review of epidemiology, pathophysiology, clinical features, diagnosis, and management.

2026-10-01T00:00:00Z

Published in Dis Mon on 1 October 2026; matched the OnCo record for Pancreatic neuroendocrine tumours.

1 October 2026, Dis Mon.

On OnCo: Pancreatic neuroendocrine tumours

Paper: Integrated Assessment of Sarcopenia in Patients with Gastric Cancer Using Deep Learning and Radiomics.

2026-10-01T00:00:00Z

Published in J Cachexia Sarcopenia Muscle on 1 October 2026; matched the OnCo record for CT body composition and sarcopenia measurement.

1 October 2026, J Cachexia Sarcopenia Muscle.

On OnCo: CT body composition and sarcopenia measurement

Paper: Integrated omics-driven discovery reveals synphilin-1-mediated anoikis resistance through p53 down-regulation.

2026-10-01T00:00:00Z

Published in Biosci Rep on 1 October 2026; matched the OnCo record for SNCAIP.

1 October 2026, Biosci Rep.

On OnCo: SNCAIP

Paper: Integrating a Tumor Size-Overall Survival Model Into a Spatial Quantitative Systems Pharmacology Framework for Antibody-Drug Conjugates in Non-Small Cell Lung Cancer.

2026-10-01T00:00:00Z

Published in CPT Pharmacometrics Syst Pharmacol on 1 October 2026; matched the OnCo record for Trastuzumab deruxtecan.

1 October 2026, CPT Pharmacometrics Syst Pharmacol.

On OnCo: Trastuzumab deruxtecan

Paper: JARID2 inhibition reprograms human hematopoietic progenitor cells to enhance bone marrow transplantation.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched EZH2 and STAT1.

1 October 2026.

On OnCo: EZH2, STAT1

Paper: KDM2B controls HIF levels and activity through its JmjC and CxxC domains.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched HIF-1α.

1 October 2026.

On OnCo: HIF-1α

Paper: Macrophage FOXO1 Inhibition Protects Against Hyperglycaemia-Associated Kidney Injury.

2026-10-01T00:00:00Z

Published in Basic Clin Pharmacol Toxicol on 1 October 2026; matched the OnCo record for FOXO1.

1 October 2026, Basic Clin Pharmacol Toxicol.

On OnCo: FOXO1

Paper: Management of Hemangiomas.

2026-10-01T00:00:00Z

Published in Clin Plast Surg on 1 October 2026; matched the OnCo record for Propranolol.

1 October 2026, Clin Plast Surg.

On OnCo: Propranolol

Paper: MiR-376c-3p Targets STRBP mRNA to Regulate Cashmere Goat Hair Follicle Stem Cell Proliferation and Multipotency by Inhibiting the Wnt/β-Catenin and BMP Signaling Pathways.

2026-10-01T00:00:00Z

Published in Anim Genet on 1 October 2026; matched the OnCo record for SOX9.

1 October 2026, Anim Genet.

On OnCo: SOX9

Paper: Molecular basis of high-torque transmission of the Vibrio polar flagellar motor.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched LPA.

1 October 2026.

On OnCo: LPA

Paper: Multimodal Ageing Biomarkers and Plasma Proteomic Signatures Associated With All-Cause Mortality.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics, Epigenetic age after cancer treatment and Telomere length after treatment.

1 October 2026.

On OnCo: Proteomics & phosphoproteomics, Epigenetic age after cancer treatment, Telomere length after treatment, TIMP1

Paper: New Observations on a Low-Grade Diffusely Infiltrative Tumour, SMARCB1 Mutant, Arguing for a New Tumour Type.

2026-10-01T00:00:00Z

Published in Neuropathol Appl Neurobiol on 1 October 2026; matched the OnCo record for SMARCB1.

1 October 2026, Neuropathol Appl Neurobiol.

On OnCo: SMARCB1

Paper: Non-Meningothelial Mesenchymal Tumor of the Central Nervous System: Case Report and Literature Review.

2026-10-01T00:00:00Z

Published in Neuropathology on 1 October 2026; matched the OnCo record for CIC.

1 October 2026, Neuropathology.

On OnCo: CIC

Paper: Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study.

2026-10-01T00:00:00Z

Published in J Immunother on 1 October 2026; matched the OnCo record for Extensive-stage small-cell lung cancer.

1 October 2026, J Immunother.

On OnCo: Extensive-stage small-cell lung cancer, Platinum + etoposide

Paper: Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial.

2026-10-01T00:00:00Z

Published in Cancer on 1 October 2026; matched the OnCo record for TET2.

1 October 2026, Cancer.

On OnCo: TET2

Paper: Pancreatic Cancer Disrupts Circadian Patterns of Gene Expression in Cardiorespiratory Muscles.

2026-10-01T00:00:00Z

Published in J Cachexia Sarcopenia Muscle on 1 October 2026; matched the OnCo record for REST.

1 October 2026, J Cachexia Sarcopenia Muscle.

On OnCo: REST

Paper: Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors.

2026-10-01T00:00:00Z

Published in Hematol Oncol Clin North Am on 1 October 2026; matched the OnCo record for Gastrointestinal stromal tumour.

1 October 2026, Hematol Oncol Clin North Am.

On OnCo: Gastrointestinal stromal tumour

Paper: Predicting Relevant Microglia-Associated Cell-Cell Communication Pathways in Alzheimer's Disease: A Role for SPP1.

2026-10-01T00:00:00Z

Published in Glia on 1 October 2026; matched the OnCo record for AXL.

1 October 2026, Glia.

On OnCo: AXL, GAS6, ITGAV

Paper: Prevalence and Clinical Significance of Abnormal Findings on Pre-Diagnostic Imaging in Pancreatic Ductal Adenocarcinoma.

2026-10-01T00:00:00Z

Published in Pancreas on 1 October 2026; matched the OnCo record for Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors.

1 October 2026, Pancreas.

On OnCo: Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors

Paper: Primary Cerebral Pleomorphic-Myxoid Sarcoma With Many Hyaline Globules.

2026-10-01T00:00:00Z

Published in Neuropathology on 1 October 2026; matched the OnCo record for DICER1.

1 October 2026, Neuropathology.

On OnCo: DICER1

Paper: Primary pulmonary salivary gland-type tumors in cytopathology practice: A systematic review and meta-analysis.

2026-10-01T00:00:00Z

Published in Cancer Cytopathol on 1 October 2026; matched the OnCo record for Mucoepidermoid carcinoma.

1 October 2026, Cancer Cytopathol.

On OnCo: Mucoepidermoid carcinoma, Salivary gland cancers

Paper: Progressive remodeling of global protein interaction networks in a mouse model of tauopathy.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics, Atlas and State.

1 October 2026.

On OnCo: Proteomics & phosphoproteomics, Atlas, State, MSN

Paper: Protracted Fate Acquisition and Epigenetic De-Aging During Induced Neural Stem Cell Conversion of Human Blood Cells.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, DNA methylation profiling and PAX6.

1 October 2026.

On OnCo: RNA sequencing & expression profiling, DNA methylation profiling, PAX6, SOX2

Paper: PSEN1 Expression Identifies a Developmentally Distinct Favourable-Prognosis State in SHH α Medulloblastoma.

2026-10-01T00:00:00Z

Published in Int J Dev Neurosci on 1 October 2026; matched the OnCo record for Gamma-secretase.

1 October 2026, Int J Dev Neurosci.

On OnCo: Gamma-secretase, Medulloblastoma

Paper: Pulmonary Tuberculosis in Rhesus Macaque (Macaca mulatta): A Case Report.

2026-10-01T00:00:00Z

Published in J Med Primatol on 1 October 2026; matched the OnCo record for Medullary thyroid cancer.

1 October 2026, J Med Primatol.

On OnCo: Medullary thyroid cancer

Paper: Rates of Evolution Differ Between Cell Types Identified by Single-Cell RNAseq in Threespine Stickleback.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling and Single-cell & spatial profiling.

1 October 2026.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling

Paper: Research on the impact of different chemotherapy and targeted therapy regimens on postoperative disease-free survival in breast cancer patients.

2026-10-01T00:00:00Z

Published in Pak J Pharm Sci on 1 October 2026; matched the OnCo record for Capecitabine.

1 October 2026, Pak J Pharm Sci.

On OnCo: Capecitabine

Paper: Resolution and Quantitation of Ribonucleosides and Deoxyribonucleosides in Digested Genomic DNA by UHPLC-MS/MS.

2026-10-01T00:00:00Z

Published in Biomed Chromatogr on 1 October 2026; matched the OnCo record for Ceralasertib.

1 October 2026, Biomed Chromatogr.

On OnCo: Ceralasertib

Paper: Responsiveness, Smallest Detectable Change, and Minimal Important Change of the Turkish Pelvic Floor Distress Inventory-20 Following Pelvic Floor Muscle Training.

2026-10-01T00:00:00Z

Published in Physiother Res Int on 1 October 2026; matched the OnCo record for Salivary duct carcinoma.

1 October 2026, Physiother Res Int.

On OnCo: Salivary duct carcinoma

Paper: Sequence Inversion Dictates the Antiproliferative Activity of Bidirectional Tryptophan-Containing Dipeptide Libraries.

2026-10-01T00:00:00Z

Published in J Pept Sci on 1 October 2026; matched the OnCo record for Mia.

1 October 2026, J Pept Sci.

On OnCo: Mia

Paper: Sequentially Self-Assembled Supramolecular Nanocomplexes Enable Systemic Cas9 RNP Delivery and In Vivo Tumor Genome Editing.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched Pertuzumab and PLK1.

1 October 2026.

On OnCo: Pertuzumab, PLK1

Paper: Supporting implementation of the national standards for cancer survivorship care: development of the cancer survivorship maturity model (CSMM).

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched CCDC6.

1 October 2026.

On OnCo: CCDC6

Paper: Talimogene Laherparepvec Response in Recurrent Melanoma During Corticosteroid Replacement for Immune Checkpoint Inhibitor-Induced Adrenal Insufficiency: A Case Report.

2026-10-01T00:00:00Z

Published in J Immunother on 1 October 2026; matched the OnCo record for Talimogene laherparepvec.

1 October 2026, J Immunother.

On OnCo: Talimogene laherparepvec

Paper: Temporal gating dictates stress-induced transcript export from the nucleus.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched JUN, FOS and HMOX1.

1 October 2026.

On OnCo: JUN, FOS, HMOX1

Paper: The Impact of the Number and the Size of Clusters on Prediction Performance of the Stratified and the Conditional Shared Gamma Frailty Cox Proportional Hazards Models.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched SET.

1 October 2026.

On OnCo: SET

Paper: The mitochondrial chaperone HSPD1 folds MTHFD2 independently of its co-chaperone HSPE1.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics.

1 October 2026.

On OnCo: Proteomics & phosphoproteomics

Paper: The Mitochondrial ubiquitin ligase MARCHF5 cooperates with MCL1 to inhibit Apoptosis in KSHV-transformed primary effusion lymphoma cell lines.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched Cytotoxic chemotherapy, Proteasome and MCL1.

1 October 2026.

On OnCo: Cytotoxic chemotherapy, Proteasome, MCL1

Paper: The Role and Meaning of Hospital Food for Culturally and Linguistically Diverse Patients.

2026-10-01T00:00:00Z

Published on 1 October 2026 after first appearing as a preprint; matched CCDC6.

1 October 2026.

On OnCo: CCDC6

Paper: The use of locoregional therapies in cholangiocarcinoma.

2026-10-01T00:00:00Z

Published in J Hepatol on 1 October 2026; matched the OnCo record for Floxuridine.

1 October 2026, J Hepatol.

On OnCo: Floxuridine, Radioembolisation, Transarterial chemoembolisation

Paper: Understanding Barriers and Motivators of Familial Hypercholesterolemia Genetic Testing: Insights From the Singapore Public.

2026-10-01T00:00:00Z

Published in J Genet Couns on 1 October 2026; matched the OnCo record for FH.

1 October 2026, J Genet Couns.

On OnCo: FH

Paper: Weird, Witty and Worthwhile: Exploring the Benefits of Mnemonic-Based Medical Education.

2026-10-01T00:00:00Z

Published in Clin Teach on 1 October 2026; matched the OnCo record for Small intestine cancer.

1 October 2026, Clin Teach.

On OnCo: Small intestine cancer, CCDC6

Paper: CAR signaling instructs divergent metabolic reprogramming and functional fates in αβ and γδ T cells.

2026-09-30T00:00:00Z

Published on 30 September 2026 after first appearing as a preprint; matched CAR-T cell therapy, JUN and PSCA.

30 September 2026.

On OnCo: CAR-T cell therapy, JUN, PSCA, FOS, FOSB

Paper: CDK7, CDK9, or CDK11 inhibition reduces neutrophil-driven inflammation and tissue damage in experimental autoimmune models.

2026-09-30T00:00:00Z

Published on 30 September 2026 after first appearing as a preprint; matched CDK4/6, CDK12 and CDK9.

30 September 2026.

On OnCo: CDK4/6, CDK12, CDK9, CDK2

Paper: Changes in the translational landscape during red clover necrotic mosaic virus infection.

2026-09-30T00:00:00Z

Published on 30 September 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling.

30 September 2026.

On OnCo: RNA sequencing & expression profiling

Paper: Distinct phases of immune system programming during ART-suppressed immunodeficiency virus infection.

2026-09-30T00:00:00Z

Published on 30 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.

30 September 2026.

On OnCo: Single-cell & spatial profiling

Paper: Greatwall kinase regulates acute myeloid leukaemia cell division through a non-canonical mechanism.

2026-09-30T00:00:00Z

Published on 30 September 2026 after first appearing as a preprint; matched MARK3.

30 September 2026.

On OnCo: MARK3

Paper: Hyperactive STAT1 Promotes T Follicular Helper Type 1 Cell Differentiation to Trigger Autoimmunity.

2026-09-30T00:00:00Z

Published on 30 September 2026 after first appearing as a preprint; matched STAT1.

30 September 2026.

On OnCo: STAT1

Paper: Immune markers mediate genetic relationships between immune diseases and psychiatric disorders.

2026-09-30T00:00:00Z

Published on 30 September 2026 after first appearing as a preprint; matched Interleukin-6 and IL-6 receptor.

30 September 2026.

On OnCo: Interleukin-6 and IL-6 receptor

Paper: LAT condensation gates PLCγ1 activation via bimodal LAT phosphorylation.

2026-09-30T00:00:00Z

Published on 30 September 2026 after first appearing as a preprint; matched Logic-gated therapeutics, State and TEC.

30 September 2026.

On OnCo: Logic-gated therapeutics, State, TEC

Paper: Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance.

2026-09-30T00:00:00Z

Published on 30 September 2026 after first appearing as a preprint; matched Nintedanib, KRAS & RAS inhibitors and Genetically engineered mouse models.

30 September 2026.

On OnCo: Nintedanib, KRAS & RAS inhibitors, Genetically engineered mouse models, KRAS, State, NKX2-1

Paper: Novel KIR2DS4:HLA-B35 interaction predicts HLA-B35 positive patient survival post hematopoietic stem cell transplant.

2026-09-30T00:00:00Z

Published on 30 September 2026 after first appearing as a preprint; matched HLA-A, TNFRSF10B and HLA-B.

30 September 2026.

On OnCo: HLA-A, TNFRSF10B, HLA-B, KIR2DL1

Paper: Plasma Proteome-Wide Mendelian Randomization with Multi-Layer Triangulation Identifies Druggable Targets for Uterine Leiomyoma.

2026-09-30T00:00:00Z

Published on 30 September 2026 after first appearing as a preprint; matched PARP inhibitors, PARP and RSPO3.

30 September 2026.

On OnCo: PARP inhibitors, PARP, RSPO3, EIF2AK3

Paper: Programmable DNA protonuclei reveal environmental context on protein phase separation.

2026-09-30T00:00:00Z

Published on 30 September 2026 after first appearing as a preprint; matched FUS.

30 September 2026.

On OnCo: FUS

Paper: Salicylic acid engages central metabolic regulators SnRK1 and TOR to govern immunity by differential phosphorylation of NPR1.

2026-09-30T00:00:00Z

Published on 30 September 2026 after first appearing as a preprint; matched Sirolimus.

30 September 2026.

On OnCo: Sirolimus

Paper: Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibition.

2026-09-30T00:00:00Z

Published on 30 September 2026 after first appearing as a preprint; matched Antibody-drug conjugate, Topoisomerase I and MYC.

30 September 2026.

On OnCo: Antibody-drug conjugate, Topoisomerase I, MYC

Paper: Targeted extracellular degradation of LRP8 promotes ferroptosis in cancer cells.

2026-09-30T00:00:00Z

Published on 30 September 2026 after first appearing as a preprint; matched LPA and MCLA-129.

30 September 2026.

On OnCo: LPA, MCLA-129

Paper: Androgen Deprivation Therapy (ADT) and Radiotherapy (RT) with Imaging Evaluation Longitudinally (ARIEL) trial: protocol, early results, and implications of neoadjuvant ADT for focal RT boost in prostate cancer.

2026-09-29T00:00:00Z

Published on 29 September 2026 after first appearing as a preprint; matched Multiparametric prostate MRI, Androgen deprivation & AR pathway inhibitors and MET.

29 September 2026.

On OnCo: Multiparametric prostate MRI, Androgen deprivation & AR pathway inhibitors, MET, ELL

Paper: Can We Extend Beyond 2 Years of Adjuvant ALK TKI Established by ALINA and ELEVATE in Resected Early Stage ALK+ NSCLC a Disease with High Predilection for CNS Metastasis with Novel Clinical Trial Designs?

2026-09-29T00:00:00Z

Published in Lung Cancer (Auckl) on 29 September 2026; found by the roadmap watch for ALINA.

29 September 2026, Lung Cancer (Auckl).

On OnCo: ALINA, Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall

Paper: CSGDA: A Cell State-Guided Graph Domain Adaptation Network for Single-Cell Drug Response Prediction.

2026-09-29T00:00:00Z

Published on 29 September 2026 after first appearing as a preprint; matched Cisplatin, Single-cell & spatial profiling and Platinum agents.

29 September 2026.

On OnCo: Cisplatin, Single-cell & spatial profiling, Platinum agents, State

Paper: Long-Term Human Skin Platform for Modeling Chronic Inflammation, Environmental Stress, and Therapeutic Intervention.

2026-09-29T00:00:00Z

Published on 29 September 2026 after first appearing as a preprint; matched Senolytics after cancer treatment.

29 September 2026.

On OnCo: Senolytics after cancer treatment

Paper: Loss of PIMREG impairs double-strand break signaling and repair.

2026-09-29T00:00:00Z

Published on 29 September 2026 after first appearing as a preprint; matched Temozolomide, ATR and ATM.

29 September 2026.

On OnCo: Temozolomide, ATR, ATM

Paper: Network of interactions between the tumor necrosis factor superfamily members and small S100 proteins.

2026-09-29T00:00:00Z

Published on 29 September 2026 after first appearing as a preprint; matched CD70 and TNFSF10.

29 September 2026.

On OnCo: CD70, TNFSF10

Paper: Single-cell spatial mapping reveals reproducible cell type organization and spatially dependent gene expression in gastruloids.

2026-09-29T00:00:00Z

Published on 29 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.

29 September 2026.

On OnCo: Single-cell & spatial profiling

Paper: Spatial modulation of RAF by RAF/MEK glue enables full-dose combination with pan-RAF inhibitor and potent RAS-mutant tumor-selective MAPK and growth inhibition.

2026-09-29T00:00:00Z

Published on 29 September 2026 after first appearing as a preprint; matched ARAF.

29 September 2026.

On OnCo: ARAF

Paper: Spatial transcriptomic analysis of progressing oral epithelial dysplasia reveals unique differentially expressed genes and microenvironmental changes.

2026-09-29T00:00:00Z

Published on 29 September 2026 after first appearing as a preprint; matched Azacitidine, Decitabine + cedazuridine and Single-cell & spatial profiling.

29 September 2026.

On OnCo: Azacitidine, Decitabine + cedazuridine, Single-cell & spatial profiling, Spatial transcriptomics

Paper: Spatiotemporal modeling of GPCR signaling: The role of endosomal dynamics and receptor recycling.

2026-09-29T00:00:00Z

Published on 29 September 2026 after first appearing as a preprint; matched Abiraterone acetate, Docetaxel and Cisplatin.

29 September 2026.

On OnCo: Abiraterone acetate, Docetaxel, Cisplatin, Leucovorin

Paper: Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study.

2026-09-22T00:00:00Z

Published in Nat Med on 22 September 2026; found by the roadmap watch for PATHFINDER 2.

22 September 2026, Nat Med.

On OnCo: PATHFINDER 2, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Early detection roadmap: organ screening → blood tests for many cancers

Paper: Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial.

2026-09-22T00:00:00Z

Published in Nat Med on 22 September 2026; found by the roadmap watch for NHS-Galleri.

22 September 2026, Nat Med.

On OnCo: NHS-Galleri, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Early detection roadmap: organ screening → blood tests for many cancers

Paper: Switching of transcriptional control from interferon regulatory factor 2 to interferon regulatory factor 1 drives innate immune cell activation.

2026-09-22T00:00:00Z

Published in Cell on 22 September 2026; matched the OnCo record for IRF1.

22 September 2026, Cell.

On OnCo: IRF1, SPOP

Paper: The liver niche accelerates, while the lung niche restrains secondary spread of breast cancer.

2026-09-22T00:00:00Z

Published in Cancer Discov on 22 September 2026; matched the OnCo record for BMP2.

22 September 2026, Cancer Discov.

On OnCo: BMP2

Paper: A role for heavy chain-modification in protecting hyaluronan from free radical fragmentation during inflammation.

2026-09-28T00:00:00Z

Published on 28 September 2026 after first appearing as a preprint; matched State and CLTC.

28 September 2026.

On OnCo: State, CLTC

Paper: Aboriginal and Torres Strait Islander adolescent and parent perspectives on human papillomavirus vaccination through the School Immunisation Program in Queensland, Australia: a qualitative study.

2026-09-28T00:00:00Z

Published on 28 September 2026 after first appearing as a preprint; matched HPV & HBV vaccination and SET.

28 September 2026.

On OnCo: HPV & HBV vaccination, SET

Paper: EXCEL-Punjabi: the process of using a community based participatory research approach for a culturally-tailored exercise oncology intervention.

2026-09-28T00:00:00Z

Published on 28 September 2026 after first appearing as a preprint; matched Exercise & lifestyle oncology.

28 September 2026.

On OnCo: Exercise & lifestyle oncology

Paper: Exploiting an epigenetic resistance mechanism to PI3-kinase inhibition in leukemic stem cells.

2026-09-28T00:00:00Z

Published on 28 September 2026 after first appearing as a preprint; matched EZH2.

28 September 2026.

On OnCo: EZH2

Paper: Genetic and cellular architecture of breast cancer risk across ancestries.

2026-09-28T00:00:00Z

Published on 28 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling and Atlas.

28 September 2026.

On OnCo: Single-cell & spatial profiling, Atlas

Paper: Impact of Socioeconomic Status on Early Gastric Cancer Outcomes and Treatment Disparity: a SEER analysis.

2026-09-28T00:00:00Z

Published on 28 September 2026 after first appearing as a preprint; matched EDNRA.

28 September 2026.

On OnCo: EDNRA

Paper: Interpretable machine learning models for predicting tocilizumab response in rheumatoid arthritis using clinical data.

2026-09-28T00:00:00Z

Published on 28 September 2026 after first appearing as a preprint; matched Tocilizumab.

28 September 2026.

On OnCo: Tocilizumab

Paper: Low birthweight and prematurity, but not malaria chemoprevention, are associated with reduced pneumococcal vaccine immunogenicity in Ugandan infants.

2026-09-28T00:00:00Z

Published on 28 September 2026 after first appearing as a preprint; matched Chemoprevention & risk-reducing surgery.

28 September 2026.

On OnCo: Chemoprevention & risk-reducing surgery

Paper: MCM10 and SLD-2/RECQL4 jointly activate the CMG helicase during metazoan DNA replication initiation.

2026-09-28T00:00:00Z

Published on 28 September 2026 after first appearing as a preprint; matched Synthetic lethality approaches and RECQL4.

28 September 2026.

On OnCo: Synthetic lethality approaches, RECQL4

Paper: Perspectives of women and healthcare providers on facilitators and barriers to cervical cancer screening in the rural Kilimanjaro region Tanzania: a qualitative study.

2026-09-28T00:00:00Z

Published on 28 September 2026 after first appearing as a preprint; matched CCDC6.

28 September 2026.

On OnCo: CCDC6

Paper: Population Pharmacokinetics and Exposure-response Analysis of Durvalumab in Patients with Limited-stage Small-cell Lung Cancer in the Phase 3 ADRIATIC Study.

2026-09-28T00:00:00Z

Published in AAPS J on 28 September 2026; found by the roadmap watch for ADRIATIC.

28 September 2026, AAPS J.

On OnCo: ADRIATIC, Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch

Paper: Risk-reducing salpingo-oophorectomy in patients with gBRCA-mutated breast cancer.

2026-09-28T00:00:00Z

Published on 28 September 2026 after first appearing as a preprint; matched HER2, BRCA1 / BRCA2 and EGF.

28 September 2026.

On OnCo: HER2, BRCA1 / BRCA2, EGF

Paper: The Beekeeping Sector of Kazakhstan and Contributions to the Pharmaceutical Industry: Promising Flavonoids with the Pharmacokinetic Properties Via the Computational Evaluations.

2026-09-28T00:00:00Z

Published on 28 September 2026 after first appearing as a preprint; matched ABCB1.

28 September 2026.

On OnCo: ABCB1

Paper: The relationship between activities of daily living, frailty, and care dependency in older adults with lung cancer.

2026-09-28T00:00:00Z

Published on 28 September 2026 after first appearing as a preprint; matched MET and Frailty and late effects in survivors.

28 September 2026.

On OnCo: MET, Frailty and late effects in survivors

Paper: UHRF1 overexpression generates distinct senescent states with different Tp53 dependencies.

2026-09-28T00:00:00Z

Published on 28 September 2026 after first appearing as a preprint; matched TP53, Senolytics after cancer treatment and ATM.

28 September 2026.

On OnCo: TP53, Senolytics after cancer treatment, ATM, Navitoclax

Paper: Melatonin, circadian metabolism, mitochondrial remodeling, and cell size dynamics in primitive hematopoietic stem cells.

2026-09-21T00:00:00Z

Published in Blood on 21 September 2026; matched the OnCo record for LMNA.

21 September 2026, Blood.

On OnCo: LMNA

Paper: Acoustically Activatable Drug-Loaded Nanodroplets for Mechanochemical Therapy in Solid Tumors.

2026-09-27T00:00:00Z

Published on 27 September 2026 after first appearing as a preprint; matched Ultrasound.

27 September 2026.

On OnCo: Ultrasound

Paper: Is a Few Too Many? Alcohol Consumption and Prostate Cancer Upgrading During Active Surveillance.

2026-09-27T00:00:00Z

Published on 27 September 2026 after first appearing as a preprint; matched Active surveillance and ELL.

27 September 2026.

On OnCo: Active surveillance, ELL

Paper: Autoencoders for unsupervised analysis of rat myeloarchitecture.

2026-09-26T00:00:00Z

Published on 26 September 2026 after first appearing as a preprint; matched Pathology & radiology foundation models.

26 September 2026.

On OnCo: Pathology & radiology foundation models

Paper: Collagen targeting IL-12 combined with doxorubicin enhances the anti-tumor effect against osteosarcoma.

2026-09-26T00:00:00Z

Published on 26 September 2026 after first appearing as a preprint; matched Doxorubicin and VWF.

26 September 2026.

On OnCo: Doxorubicin, VWF

Paper: Primary ALK-positive anaplastic large cell lymphoma of the urinary bladder in a pediatric patient: a case report and review of literature.

2026-09-26T00:00:00Z

Published on 26 September 2026 after first appearing as a preprint; matched CD30, CT and ALK.

26 September 2026.

On OnCo: CD30, CT, ALK, Brentuximab vedotin

Paper: Stem cell morphology defines functional heterogeneity and therapeutic vulnerabilities in glioblastoma.

2026-09-26T00:00:00Z

Published on 26 September 2026 after first appearing as a preprint; matched Temozolomide, Single-cell & spatial profiling and Patient-derived organoids.

26 September 2026.

On OnCo: Temozolomide, Single-cell & spatial profiling, Patient-derived organoids, Spatial transcriptomics, State

Paper: Unexpected functional role of the transactivation domain for nuclear import of STAT5.

2026-09-26T00:00:00Z

Published on 26 September 2026 after first appearing as a preprint; matched Erythropoietin receptor and STAT5.

26 September 2026.

On OnCo: Erythropoietin receptor, STAT5

Paper: Converting lysosomes into photothermal organelles enables nanoparticle-free tumor ablation via intracellular vapor bubbles.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched Sunitinib.

25 September 2026.

On OnCo: Sunitinib

Paper: Differential methylation at novel putative imprinting control regions on chromosome 20 associated with childhood obesity.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched DNA methylation profiling.

25 September 2026.

On OnCo: DNA methylation profiling

Paper: Evolution of occupational health risks among waste incinerator workers: A four-decade review.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched CFLAR.

25 September 2026.

On OnCo: CFLAR

Paper: FACT-(H3-H4) complex stimulates Pol α activity to coordinate DNA synthesis with nucleosome assembly.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched H3C14.

25 September 2026.

On OnCo: H3C14

Paper: Fast structural search for classification of gut bacterial mucin O-glycan degrading enzymes.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched State.

25 September 2026.

On OnCo: State

Paper: Fe3O4-Au cluster-satellite particles as direct colorimetric reporters in a smartphone-quantified lateral flow immunoassay for prostate-specific antigen.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched KLK2 and KLK3.

25 September 2026.

On OnCo: KLK2, KLK3

Paper: Interdisciplinary management and genetic evaluation of pediatric cancer predisposition syndromes: a retrospective cohort study.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched Germline (hereditary) testing.

25 September 2026.

On OnCo: Germline (hereditary) testing

Paper: Optical microscopy predictions of focal recurrence in glioblastoma.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched Cytotoxic chemotherapy.

25 September 2026.

On OnCo: Cytotoxic chemotherapy

Paper: PDLIM2 in lung adenocarcinoma metastasis.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched KRAS, TP53 and ELL.

25 September 2026.

On OnCo: KRAS, TP53, ELL

Paper: Preoperative Noninvasive Assessment for Predicting Steatosis Grade in Hepatocellular Carcinoma Patients with Chronic Hepatitis B: Comparison of Attenuation Imaging with Controlled Attenuation Parameter.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched Ultrasound, PSMD2 and PSMD1.

25 September 2026.

On OnCo: Ultrasound, PSMD2, PSMD1, TG

Paper: Proteomic study for the prediction of μ CT imaging with iodine.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched Atlas, FLG and SET.

25 September 2026.

On OnCo: Atlas, FLG, SET

Paper: Specific targeting of MR1-antigen complexes using nanobodies.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched Bispecific antibodies, CD3 and HLA-A.

25 September 2026.

On OnCo: Bispecific antibodies, CD3, HLA-A, MCLA-129

Paper: Topologically-based parameter inference for agent-based model selection from spatiotemporal cellular data.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling and Nicheformer.

25 September 2026.

On OnCo: Single-cell & spatial profiling, Nicheformer

Paper: Two Glu/Asp residues cooperatively mediate an early step of ATP hydrolysis in GHKL ATPases MutL and GyrB.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched State, Mismatch repair proteins and MLH1.

25 September 2026.

On OnCo: State, Mismatch repair proteins, MLH1, PMS2, HSP90AA1

Paper: Umbilical Cord Mesenchymal Stem Cells Improve PINK1/PARKIN-Mediated Mitophagy Inhibition in Preeclampsia.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched Mesenchymal stromal cells for tissue damage.

25 September 2026.

On OnCo: Mesenchymal stromal cells for tissue damage

Paper: Association Between Patient-Reported Outcomes and Health Care Resource Utilization: Toward Developing Patient-Centered Value Measures in Cancer Care.

2026-09-18T00:00:00Z

Published in J Clin Oncol on 18 September 2026; matched the OnCo record for Early-stage classical Hodgkin lymphoma.

18 September 2026, J Clin Oncol.

On OnCo: Early-stage classical Hodgkin lymphoma

Paper: Phase III Trials Test First-Line Options in Advanced NSCLC.

2026-09-18T00:00:00Z

Published in Cancer Discov on 18 September 2026; matched the OnCo record for Amivantamab.

18 September 2026, Cancer Discov.

On OnCo: Amivantamab, Ivonescimab, Zipalertinib

Paper: γδ T cells modulate anti-tumor immunity in small cell lung cancer.

2026-09-18T00:00:00Z

Published in Cancer Cell on 18 September 2026; matched the OnCo record for Zoledronic acid.

18 September 2026, Cancer Cell.

On OnCo: Zoledronic acid, Single-cell & spatial profiling, T-cell engagers, DLL3, CD3, PD-1, PD-L1

Paper: A CRISPR-Based Humanized Model Reveals Cooperative Role of STAG2 Loss in Familial GATA2-Deficient MDS Progression.

2026-09-24T00:00:00Z

Published on 24 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling, GATA2 and STAG2.

24 September 2026.

On OnCo: Single-cell & spatial profiling, GATA2, STAG2

Paper: A rare ATM variant in a Colombian family with chorea-ataxia syndrome: implications for an early diagnosis.

2026-09-24T00:00:00Z

Published on 24 September 2026 after first appearing as a preprint; matched Whole-exome & whole-genome sequencing and ATM.

24 September 2026.

On OnCo: Whole-exome & whole-genome sequencing, ATM

Paper: ASCL1 and OLIG2 Expression Dynamics Control Glial Cell Fate and Regional Diversity in the Dorsal Forebrain.

2026-09-24T00:00:00Z

Published on 24 September 2026 after first appearing as a preprint; matched State, ASCL1 and OLIG2.

24 September 2026.

On OnCo: State, ASCL1, OLIG2

Paper: DesignMaster: A Multi-Conditional Diffusion Framework for Rational PROTAC Design.

2026-09-24T00:00:00Z

Published on 24 September 2026 after first appearing as a preprint; matched PROTACs & molecular glues.

24 September 2026.

On OnCo: PROTACs & molecular glues

Paper: Exploring the feasibility of exercise training during (neo)adjuvant chemotherapy in women with early-stage breast cancer: a pilot study examining immune and metabolic outcomes.

2026-09-24T00:00:00Z

Published on 24 September 2026 after first appearing as a preprint; matched Exercise & lifestyle oncology.

24 September 2026.

On OnCo: Exercise & lifestyle oncology

Paper: Phylogenetic and phylodynamic approaches to understanding the evolution of non-small cell lung cancer using single-cell sequencing.

2026-09-24T00:00:00Z

Published on 24 September 2026 after first appearing as a preprint; matched Nintedanib, Whole-exome & whole-genome sequencing and Single-cell & spatial profiling.

24 September 2026.

On OnCo: Nintedanib, Whole-exome & whole-genome sequencing, Single-cell & spatial profiling

Paper: Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study.

2026-09-24T00:00:00Z

Published on 24 September 2026 after first appearing as a preprint; matched BTK, Pirtobrutinib and State.

24 September 2026.

On OnCo: BTK, Pirtobrutinib, State

Paper: Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?

2026-09-24T00:00:00Z

Published in Eur J Cancer on 24 September 2026; found by the roadmap watch for KEYNOTE-522.

24 September 2026, Eur J Cancer.

On OnCo: KEYNOTE-522, Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity, Surgery roadmap: radical operations → less surgery → no surgery when a drug has done the work, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem

Paper: Selective dependency of CALR-mutant myeloproliferative neoplasms on TYK2 signaling.

2026-09-24T00:00:00Z

Published on 24 September 2026 after first appearing as a preprint; matched Fedratinib, JAK2 and MPL.

24 September 2026.

On OnCo: Fedratinib, JAK2, MPL, CALR, TYK2, EDNRA

Paper: An expert-level generalist AI for abdominal CT diagnosis.

2026-09-17T00:00:00Z

Published in Science on 17 September 2026; matched the OnCo record for RaDaR.

17 September 2026, Science.

On OnCo: RaDaR

Paper: Anti-B7-H3 ADCs Take Center Stage against SCLC at WCLC.

2026-09-17T00:00:00Z

Published in Cancer Discov on 17 September 2026; matched the OnCo record for YL201.

17 September 2026, Cancer Discov.

On OnCo: YL201

Paper: Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma.

2026-09-17T00:00:00Z

Published in Nat Med on 17 September 2026; matched the OnCo record for Diffuse midline glioma, H3 K27-altered.

17 September 2026, Nat Med.

On OnCo: Diffuse midline glioma, H3 K27-altered

Paper: Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.

2026-09-17T00:00:00Z

Published in Ann Oncol on 17 September 2026; matched the OnCo record for Goserelin / leuprolide.

17 September 2026, Ann Oncol.

On OnCo: Goserelin / leuprolide

Paper: 18F-CETO in Adrenocortical Carcinoma: First Clinical-Translational Study of An Adrenocortical-targeting PET Tracer.

2026-09-23T00:00:00Z

Published in Endocr Relat Cancer on 23 September 2026; matched the OnCo record for CYP11B1.

23 September 2026, Endocr Relat Cancer.

On OnCo: CYP11B1

Paper: A human cell-free translation screen identifies the NT-2 mycotoxin as a ribosomal inhibitor that binds the peptidyl transferase center.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched Elongation factor 2 and State.

23 September 2026.

On OnCo: Elongation factor 2, State

Paper: A Metabolic-Epigenetic Axis of AARS1/IGF2BP3-K280 Lactylation Sustains Endometrial Cancer Stemness and Recurrence.

2026-09-23T00:00:00Z

Published in Adv Sci (Weinh) on 23 September 2026; matched the OnCo record for HMGA2.

23 September 2026, Adv Sci (Weinh).

On OnCo: HMGA2

Paper: A probiotic Bifidobacterium pseudocatenulatum converts hesperidin to bioactive hesperetin and improves metabolic dysfunction in aging mice.

2026-09-23T00:00:00Z

Published in Gut Microbes on 23 September 2026; matched the OnCo record for SIRT1.

23 September 2026, Gut Microbes.

On OnCo: SIRT1

Paper: Cancer-associated mutations in endometriosis reframe a benign disease through molecular oncology.

2026-09-23T00:00:00Z

Published in Mol Oncol on 23 September 2026; matched the OnCo record for ARID1A.

23 September 2026, Mol Oncol.

On OnCo: ARID1A

Paper: Efficient differential expression analysis of large-scale single-cell transcriptomics data using Dreamlet.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.

23 September 2026.

On OnCo: Single-cell & spatial profiling

Paper: Establishment of a cell line-based 3D co-culture model of the endometrium for studying endometrial receptivity.

2026-09-23T00:00:00Z

Published in Am J Physiol Cell Physiol on 23 September 2026; matched the OnCo record for HEY1.

23 September 2026, Am J Physiol Cell Physiol.

On OnCo: HEY1

Paper: Exceptional response to alpelisib in a heavily pretreated patient with metastatic breast cancer carrying a PIK3CA mutation outside SOLAR-1 eligible mutations: a case report.

2026-09-23T00:00:00Z

Published in Acta Oncol on 23 September 2026; found by the roadmap watch for SOLAR-1.

23 September 2026, Acta Oncol.

On OnCo: SOLAR-1, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test

Paper: Fast, flexible analysis of differences in cellular composition with crumblr.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.

23 September 2026.

On OnCo: Single-cell & spatial profiling

Paper: FGD1 restrains actomyosin contractility to promote suprabasal junction maturation in stratified keratinocytes.

2026-09-23T00:00:00Z

Published in J Cell Sci on 23 September 2026; matched the OnCo record for FGD1.

23 September 2026, J Cell Sci.

On OnCo: FGD1

Paper: GLG1 in cancer-associated fibroblasts promotes bladder cancer growth while limiting tumor apoptosis.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and Ki-67.

23 September 2026.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling, Ki-67, SMAD2, HSP90B1

Paper: Identification of anoikis-related and cell matrix adhesion genes in the progression of colon adenocarcinoma using bioinformatics analysis.

2026-09-23T00:00:00Z

Published in Comput Methods Biomech Biomed Engin on 23 September 2026; matched the OnCo record for SLC6A2.

23 September 2026, Comput Methods Biomech Biomed Engin.

On OnCo: SLC6A2

Paper: Integrated serum proteomics and autoantibody analyses reveal a biomarker signature predictive of flare during biologic tapering in rheumatoid arthritis.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics and SET.

23 September 2026.

On OnCo: Proteomics & phosphoproteomics, SET

Paper: Isolation and Purification-Free Digital Single-Small Extracellular Vesicle Biosensing with Scalable Plasmonic Arrays.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched Optical & fluorescence imaging, Liquid biopsy and MIR21.

23 September 2026.

On OnCo: Optical & fluorescence imaging, Liquid biopsy, MIR21

Paper: Multiomics analysis identifies RNASET2 as a potential candidate target associated with lung adenocarcinoma.

2026-09-23T00:00:00Z

Published in J Int Med Res on 23 September 2026; matched the OnCo record for RNASET2.

23 September 2026, J Int Med Res.

On OnCo: RNASET2

Paper: Mutations in untranslated non-coding regions of EGFR, AKT1 & HRAS modulate their expression regulatory networks to facilitate progression of colorectal cancer.

2026-09-23T00:00:00Z

Published in Funct Integr Genomics on 23 September 2026; matched the OnCo record for HRAS.

23 September 2026, Funct Integr Genomics.

On OnCo: HRAS

Paper: Neonatal enteric infection disrupts the microbiota-gut-brain axis through pattern recognition receptors and altered neuroimmune signaling.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched PSMC1.

23 September 2026.

On OnCo: PSMC1

Paper: nTMS-determined cortical excitability is associated with overall survival in patients with motor-eloquent glioblastoma.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched MGMT.

23 September 2026.

On OnCo: MGMT

Paper: Persistent TOP1 cleavage complexes in drug-tolerant cells drive adaptive resistance to EGFR-targeted therapies in lung cancer.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched Topotecan, EGFR and Topoisomerase I.

23 September 2026.

On OnCo: Topotecan, EGFR, Topoisomerase I, State

Paper: Structural mechanisms of SAMD9 autoinhibition and pathogenic dysregulation.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched SAMD9L and SAMD9.

23 September 2026.

On OnCo: SAMD9L, SAMD9

Paper: The influence of force on the encoding and perception of affective touch.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched CD96.

23 September 2026.

On OnCo: CD96

Paper: The lipidomic architecture of the mouse brain.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched Atlas and NBN.

23 September 2026.

On OnCo: Atlas, NBN

Paper: Urinary collagen type I degradation products as common fibrosis biomarkers in chronic diseases.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics.

23 September 2026.

On OnCo: Proteomics & phosphoproteomics

Paper: Bridging the Gap: From Molecular Residual Disease to Curative Opportunity: Circulating Tumor DNA-Guided Surveillance After Curative Resection for Stage I to III Colorectal Cancer.

2026-09-16T00:00:00Z

Published in J Clin Oncol on 16 September 2026; matched the OnCo record for Localised anal squamous cell carcinoma.

16 September 2026, J Clin Oncol.

On OnCo: Localised anal squamous cell carcinoma

Paper: Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.

2026-09-16T00:00:00Z

Published in Cancer Cell on 16 September 2026; matched the OnCo record for Adebrelimab.

16 September 2026, Cancer Cell.

On OnCo: Adebrelimab

Paper: Erratum: Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression.

2026-09-16T00:00:00Z

Published in J Clin Oncol on 16 September 2026; matched the OnCo record for Trastuzumab rezetecan.

16 September 2026, J Clin Oncol.

On OnCo: Trastuzumab rezetecan

Paper: Identification of broadly tumour-reactive γδ TCRs from multiple myeloma.

2026-09-16T00:00:00Z

Published in Nature on 16 September 2026; matched the OnCo record for HLA-C.

16 September 2026, Nature.

On OnCo: HLA-C

Paper: Mitochondrial fission factor senses and governs ferroptosis.

2026-09-16T00:00:00Z

Published in Nature on 16 September 2026; matched the OnCo record for PRKCB.

16 September 2026, Nature.

On OnCo: PRKCB

Approval: FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer

2026-09-09T00:00:00Z

On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.

9 September 2026, FDA.

On OnCo: Sevabertinib, Lung cancer, Squamous cell carcinoma of the lung, Non-small-cell lung cancer, HER2-mutant non-small-cell lung cancer, HER2

Paper: A physiology-based mathematical model of the renin-angiotensin system, bone remodeling, and calcium homeostasis: Effects of estrogen and renin-angiotensin system inhibitors.

2026-09-22T00:00:00Z

Published on 22 September 2026 after first appearing as a preprint; matched Mathematical models of cancer.

22 September 2026.

On OnCo: Mathematical models of cancer

Paper: A prostate cancer-specific super-enhancer at 1q42.3 regulates the CAPN2 and KRT19.

2026-09-22T00:00:00Z

Published in J Biol Chem on 22 September 2026; matched the OnCo record for ETV5.

22 September 2026, J Biol Chem.

On OnCo: ETV5

Paper: A USP28-BRD4 axis contributes to the acceleration of breast cancer growth by hyperglycemia.

2026-09-22T00:00:00Z

Published in Cell Rep on 22 September 2026; matched the OnCo record for USP28.

22 September 2026, Cell Rep.

On OnCo: USP28

Paper: Activation-induced cytidine deaminase sustains glycolytic flux through MYST1 acetyltransferase-dependent lactylation in hepatocellular carcinoma.

2026-09-22T00:00:00Z

Published in J Biol Chem on 22 September 2026; matched the OnCo record for CDA.

22 September 2026, J Biol Chem.

On OnCo: CDA

Paper: Application of aiAtlas Version 1.2 to Simulate Variant Gene Function Restoration and Rescue Thresholds in Rare Diseases: Validation Case Study.

2026-09-22T00:00:00Z

Published in JMIR Bioinform Biotechnol on 22 September 2026; matched the OnCo record for ERCC2.

22 September 2026, JMIR Bioinform Biotechnol.

On OnCo: ERCC2

Paper: Assessment of combined antiviral drug treatment against selected α-, β-, and γ-herpesviruses.

2026-09-22T00:00:00Z

Published on 22 September 2026 after first appearing as a preprint; matched Small-molecule kinase inhibitors, CDK4/6 inhibitors and Abemaciclib.

22 September 2026.

On OnCo: Small-molecule kinase inhibitors, CDK4/6 inhibitors, Abemaciclib

Paper: BK_Ca channel deletion modulates the DNA damage response to electron ultra-high dose rate irradiation in glioblastoma cells.

2026-09-22T00:00:00Z

Published in J Neurooncol on 22 September 2026; matched the OnCo record for TP53BP1.

22 September 2026, J Neurooncol.

On OnCo: TP53BP1

Paper: Breaking the deadlock of metallo-β-lactamases: evidence and prospects for Aztreonam/Avibactam.

2026-09-22T00:00:00Z

Published in Emerg Microbes Infect on 22 September 2026; matched the OnCo record for ATM.

22 September 2026, Emerg Microbes Infect.

On OnCo: ATM

Paper: Calcitriol alleviates ARID2-deficient gastric cancer metastasis via inhibition of the Wnt/β-catenin signaling pathway.

2026-09-22T00:00:00Z

Published in Transl Oncol on 22 September 2026; matched the OnCo record for ARID2.

22 September 2026, Transl Oncol.

On OnCo: ARID2

Paper: Cost and cost-effectiveness of alternative screening and diagnostic pathways for achieving hepatitis C elimination in the country of Georgia.

2026-09-22T00:00:00Z

Published on 22 September 2026 after first appearing as a preprint; matched Abiraterone acetate, Docetaxel and Leucovorin.

22 September 2026.

On OnCo: Abiraterone acetate, Docetaxel, Leucovorin

Paper: Development of an isavuconazole physiologically-based pharmacokinetic model for adult and pediatric populations.

2026-09-22T00:00:00Z

Published on 22 September 2026 after first appearing as a preprint; matched Azacitidine, Decitabine + cedazuridine and MAX.

22 September 2026.

On OnCo: Azacitidine, Decitabine + cedazuridine, MAX

Paper: Donor and recipient immune programs underlying delayed graft function in kidney transplantation revealed by temporal single-cell profiling.

2026-09-22T00:00:00Z

Published in Kidney Int on 22 September 2026; matched the OnCo record for AREG.

22 September 2026, Kidney Int.

On OnCo: AREG

Paper: Dynamic remodeling of the transcriptional landscape drives Merkel cell specification and mechanosensory differentiation.

2026-09-22T00:00:00Z

Published in Proc Natl Acad Sci U S A on 22 September 2026; matched the OnCo record for TUBB3.

22 September 2026, Proc Natl Acad Sci U S A.

On OnCo: TUBB3

Paper: Evaluation of the image quality index with MRI motion artifacts on tumor segmentation using deep learning.

2026-09-22T00:00:00Z

Published on 22 September 2026 after first appearing as a preprint; matched MRI.

22 September 2026.

On OnCo: MRI

Paper: Fine-tuning the lysine-arginine duet: a dietary approach to suppress tumor growth.

2026-09-22T00:00:00Z

Published in Mol Biomed on 22 September 2026; matched the OnCo record for HBB.

22 September 2026, Mol Biomed.

On OnCo: HBB, RPS29

Paper: From genomic instability to epigenetic regulation: the role of DNA repair gene variants and non-coding RNAs in colorectal carcinogenesis.

2026-09-22T00:00:00Z

Published in Nucleosides Nucleotides Nucleic Acids on 22 September 2026; matched the OnCo record for ERCC1.

22 September 2026, Nucleosides Nucleotides Nucleic Acids.

On OnCo: ERCC1, MUTYH

Paper: Genetic evaluation of encorafenib-associated kinases RAF1 and MAPK8 in pancreatic cancer: Exploratory mediation by circulating immune traits.

2026-09-22T00:00:00Z

Published in Transl Oncol on 22 September 2026; matched the OnCo record for MAPK8.

22 September 2026, Transl Oncol.

On OnCo: MAPK8

Paper: IL-15 trans-presentation at the innate-adaptive interface: mechanisms and translation in cancer immunotherapy.

2026-09-22T00:00:00Z

Published in Oncoimmunology on 22 September 2026; matched the OnCo record for IL2RB.

22 September 2026, Oncoimmunology.

On OnCo: IL2RB, IL2RG, TNFRSF10B

Paper: Integrated multi-omics identifies lineage-dependent myeloid cells recruitment and the APP-CD74 axis as an immunoregulatory target in pediatric high-grade glioma.

2026-09-22T00:00:00Z

Published on 22 September 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and State.

22 September 2026.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling, State, CD74

Paper: Integrative Genetic Analyses Identify Mitochondrial-Related Genes Associated With Female Reproductive Disorders.

2026-09-22T00:00:00Z

Published in Mol Cell Endocrinol on 22 September 2026; matched the OnCo record for ALDH2.

22 September 2026, Mol Cell Endocrinol.

On OnCo: ALDH2

Paper: Integrative profiling of multi-modal plasma cfRNA signatures enables detection and prognostic risk stratification in breast cancer.

2026-09-22T00:00:00Z

Published in Genomics on 22 September 2026; matched the OnCo record for DLST.

22 September 2026, Genomics.

On OnCo: DLST

Paper: Ki-67 expression and rates of pathologic complete response in T1cN0M0 triple-negative breast cancer: a national cancer database analysis.

2026-09-22T00:00:00Z

Published in Breast Cancer Res Treat on 22 September 2026; matched the OnCo record for Invasive lobular carcinoma of the breast.

22 September 2026, Breast Cancer Res Treat.

On OnCo: Invasive lobular carcinoma of the breast, Ki-67

Paper: Low-Grade Salivary Myoepithelial Carcinoma of the Upper Lip Harboring a Novel CARMN/miR143HG::PLAG1 Fusion.

2026-09-22T00:00:00Z

Published in Head Neck Pathol on 22 September 2026; matched the OnCo record for PLAG1.

22 September 2026, Head Neck Pathol.

On OnCo: PLAG1

Paper: Midazolam suppresses glioma progression by attenuating neuronal activity and downregulating IGF1 signaling.

2026-09-22T00:00:00Z

Published on 22 September 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, AKT and Ki-67.

22 September 2026.

On OnCo: RNA sequencing & expression profiling, AKT, Ki-67

Paper: miR-324-5p acts as an independent prognostic biomarker and inhibits pediatric medulloblastoma progression by targeting HOXA9.

2026-09-22T00:00:00Z

Published in Nucleosides Nucleotides Nucleic Acids on 22 September 2026; matched the OnCo record for HOXA9.

22 September 2026, Nucleosides Nucleotides Nucleic Acids.

On OnCo: HOXA9

Paper: Modeling Liver Cancer Molecular and Histological Features by CRISPR Editing of Porcine Hepatocytes.

2026-09-22T00:00:00Z

Published in JHEP Rep on 22 September 2026; matched the OnCo record for AXIN1.

22 September 2026, JHEP Rep.

On OnCo: AXIN1

Paper: Modular mRNA cocktail enables synergistic activation of antigen-specific T cells for cancer immunotherapy.

2026-09-22T00:00:00Z

Published in Oncoimmunology on 22 September 2026; matched the OnCo record for CD80.

22 September 2026, Oncoimmunology.

On OnCo: CD80, CTAG1B, HLA-A

Paper: Molecular underpinnings of metastatic small renal masses.

2026-09-22T00:00:00Z

Published in JCI Insight on 22 September 2026; matched the OnCo record for SRMS.

22 September 2026, JCI Insight.

On OnCo: SRMS

Paper: Obesity associated elevated leptin might contribute to paclitaxel resistance via PLCB1/IP3R1 axis in head and neck cancers.

2026-09-22T00:00:00Z

Published in Biochim Biophys Acta Mol Basis Dis on 22 September 2026; matched the OnCo record for ITPR1.

22 September 2026, Biochim Biophys Acta Mol Basis Dis.

On OnCo: ITPR1

Paper: OT-knn: A neighborhood-aware optimal transport framework for aligning spatial transcriptomics data.

2026-09-22T00:00:00Z

Published on 22 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling and Spatial transcriptomics.

22 September 2026.

On OnCo: Single-cell & spatial profiling, Spatial transcriptomics

Paper: Peripheral biomarkers of anxiety in autism and attention deficit/hyperactivity disorder.

2026-09-22T00:00:00Z

Published in Dev Neurosci on 22 September 2026; matched the OnCo record for CX3CL1.

22 September 2026, Dev Neurosci.

On OnCo: CX3CL1

Paper: POLE2 of tumor cells promotes OPN secretion based on PCLAF to drive M2 macrophage polarization in clear cell renal cell carcinoma.

2026-09-22T00:00:00Z

Published in Cancer Gene Ther on 22 September 2026; matched the OnCo record for NFATC2.

22 September 2026, Cancer Gene Ther.

On OnCo: NFATC2, POLE2

Paper: Predictive molecular signatures for successful tapering of canakinumab in systemic juvenile idiopathic arthritis.

2026-09-22T00:00:00Z

Published in Ann Rheum Dis on 22 September 2026; matched the OnCo record for BCL6.

22 September 2026, Ann Rheum Dis.

On OnCo: BCL6, MAPK1, TNFAIP3

Paper: PRMT1-SFPQ regulates intron retention to control matrix gene expression during craniofacial development.

2026-09-22T00:00:00Z

Published in Elife on 22 September 2026; matched the OnCo record for SFPQ.

22 September 2026, Elife.

On OnCo: SFPQ

Paper: Proteogenomic Analysis of HDAC4 and HDAC5 in Uveal Melanoma.

2026-09-22T00:00:00Z

Published in Mol Med on 22 September 2026; matched the OnCo record for HDAC5.

22 September 2026, Mol Med.

On OnCo: HDAC5

Paper: Real-world data from patients treated with chemotherapy for biliary tract cancer: insights from a prognostic model. ^☆.

2026-09-22T00:00:00Z

Published in JHEP Rep on 22 September 2026; matched the OnCo record for PSEN2.

22 September 2026, JHEP Rep.

On OnCo: PSEN2

Paper: Reproductive factors and the expression of stromal markers in benign breast biopsy samples.

2026-09-22T00:00:00Z

Published in Br J Cancer on 22 September 2026; matched the OnCo record for TNC.

22 September 2026, Br J Cancer.

On OnCo: TNC

Paper: Right ventricular pressure overload disturbs T-tubule maturation via MEF2D's transcriptional regulation of BIN1.

2026-09-22T00:00:00Z

Published in JCI Insight on 22 September 2026; matched the OnCo record for MEF2D.

22 September 2026, JCI Insight.

On OnCo: MEF2D

Paper: Role of the miR-1298/Bone Morphogenetic Protein 7 Axis in Colorectal Cancer.

2026-09-22T00:00:00Z

Published in J Vis Exp on 22 September 2026; matched the OnCo record for BMP7.

22 September 2026, J Vis Exp.

On OnCo: BMP7

Paper: SDCBP competes with CBL to stabilize PES1 and promote c-Myc translation in ESCC tumorigenesis.

2026-09-22T00:00:00Z

Published in Cell Rep on 22 September 2026; matched the OnCo record for CBL.

22 September 2026, Cell Rep.

On OnCo: CBL, SDCBP

Paper: Semi-automated erythema quantification in infantile haemangioma receiving propranolol: a pilot feasibility study.

2026-09-22T00:00:00Z

Published on 22 September 2026 after first appearing as a preprint; matched Propranolol.

22 September 2026.

On OnCo: Propranolol

Paper: Spatiotemporally controlled degradation of CDK6 via light-triggered ROS generation: uncovering the proximity effect-mediated dual target depletion.

2026-09-22T00:00:00Z

Published in Org Biomol Chem on 22 September 2026; matched the OnCo record for CCND3.

22 September 2026, Org Biomol Chem.

On OnCo: CCND3

Paper: Structural and functional divergence of cancer hotspot mutations in CREBBP.

2026-09-22T00:00:00Z

Published in Proc Natl Acad Sci U S A on 22 September 2026; matched the OnCo record for CREBBP.

22 September 2026, Proc Natl Acad Sci U S A.

On OnCo: CREBBP

Paper: Structural organization of TAM receptor ectodomains.

2026-09-22T00:00:00Z

Published in Biochem J on 22 September 2026; matched the OnCo record for MERTK.

22 September 2026, Biochem J.

On OnCo: MERTK

Paper: Successful management of paediatric chronic SIAD with oral urea: report of two cases.

2026-09-22T00:00:00Z

Published in J Pediatr Endocrinol Metab on 22 September 2026; matched the OnCo record for Paediatric low-grade glioma.

22 September 2026, J Pediatr Endocrinol Metab.

On OnCo: Paediatric low-grade glioma

Paper: Targeting PPP1R14B overcomes immunotherapy resistance in prostate cancer by restoring CD8⁺ T-cell infiltration via the Nrf2/CX3CL1 axis.

2026-09-22T00:00:00Z

Published in J Pathol on 22 September 2026; matched the OnCo record for CX3CL1.

22 September 2026, J Pathol.

On OnCo: CX3CL1

Paper: The Drosophila FET ortholog Cabeza is an essential cofactor for ETV4-mediated activation of GGAA microsatellite neoenhancers.

2026-09-22T00:00:00Z

Published in G3 (Bethesda) on 22 September 2026; matched the OnCo record for ETV4.

22 September 2026, G3 (Bethesda).

On OnCo: ETV4, ETV6

Paper: The pathological significance of DNA damage-inducible transcript 3 immunohistochemistry in the diagnosis of myxoid liposarcoma.

2026-09-22T00:00:00Z

Published in Rev Esp Patol on 22 September 2026; matched the OnCo record for DDIT3.

22 September 2026, Rev Esp Patol.

On OnCo: DDIT3

Paper: Tumor-induced osteomalacia caused by fibroblast growth factor 23 excess : Delayed diagnosis resulting from overlooked hypophosphatemia-A case report.

2026-09-22T00:00:00Z

Published in Wien Klin Wochenschr on 22 September 2026; matched the OnCo record for FGF23.

22 September 2026, Wien Klin Wochenschr.

On OnCo: FGF23

Paper: Unexpected neonatal ABO discrepancy revealing ABO*cisAB.05 during routine cord blood testing.

2026-09-22T00:00:00Z

Published in Transfusion on 22 September 2026; matched the OnCo record for ABO.

22 September 2026, Transfusion.

On OnCo: ABO

Paper: Uterine Tumor Resembling Ovarian Sex Cord Tumor With GREB1::NCOA2 Fusion and Neuroendocrine Marker Expression: A Case Report and Literature Review.

2026-09-22T00:00:00Z

Published in Int J Surg Pathol on 22 September 2026; matched the OnCo record for NCOA2.

22 September 2026, Int J Surg Pathol.

On OnCo: NCOA2

Paper: VGLL4 enhances PDK4 transcription and promotes metabolic dysfunction-associated fatty liver disease.

2026-09-22T00:00:00Z

Published in EMBO Rep on 22 September 2026; matched the OnCo record for CEBPA.

22 September 2026, EMBO Rep.

On OnCo: CEBPA

Paper: Author Correction: Erythropoietin receptor on cDC1s dictates immune tolerance.

2026-09-15T00:00:00Z

Published in Nature on 15 September 2026; matched the OnCo record for Erythropoietin receptor.

15 September 2026, Nature.

On OnCo: Erythropoietin receptor

Paper: Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report From the Children's Oncology Group and the LEOPARD Study.

2026-09-15T00:00:00Z

Published in J Clin Oncol on 15 September 2026; matched the OnCo record for STAG2.

15 September 2026, J Clin Oncol.

On OnCo: STAG2

Paper: Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial.

2026-09-15T00:00:00Z

Published in Nat Med on 15 September 2026; matched the OnCo record for GFH375.

15 September 2026, Nat Med.

On OnCo: GFH375

Paper: Targeting BLVRB Overcomes Immunosuppression and Potentiates Immunotherapy in Monocytic Acute Myeloid Leukemia.

2026-09-15T00:00:00Z

Published in Cancer Discov on 15 September 2026; matched the OnCo record for MAFB.

15 September 2026, Cancer Discov.

On OnCo: MAFB

Paper: Citrus reticulata Essential Oil as a Bioactive Food Ingredient: Composition Variability, Extraction, Functional Bioactivities, and Cross-Study Quantitative Analysis.

2026-09-21T00:00:00Z

Published in Food Sci Nutr on 21 September 2026; found by the roadmap watch for CROSS.

21 September 2026, Food Sci Nutr.

On OnCo: CROSS, Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs, Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH

Paper: A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.

2026-09-21T00:00:00Z

Published in Blood Cancer Discov on 21 September 2026; matched the OnCo record for Acute lymphoblastic leukaemia.

21 September 2026, Blood Cancer Discov.

On OnCo: Acute lymphoblastic leukaemia, BACH2, CD22, LEF1

Paper: An Allometric Approach to Fine-Mapping Subcortical Volume Alterations in RASopathies.

2026-09-21T00:00:00Z

Published in eNeuro on 21 September 2026; matched the OnCo record for SOS1.

21 September 2026, eNeuro.

On OnCo: SOS1

Paper: Androgens Drive SOX9 Upregulation in Injured Proximal Tubular Cells.

2026-09-21T00:00:00Z

Published in Kidney Int on 21 September 2026; matched the OnCo record for SOX9.

21 September 2026, Kidney Int.

On OnCo: SOX9, Cisplatin, Platinum agents, Androgen receptor

Paper: Assessment of Lectin Staining Biomarkers for GNE Myopathy Gene Therapy.

2026-09-21T00:00:00Z

Published in Muscle Nerve on 21 September 2026; matched the OnCo record for Small intestine cancer.

21 September 2026, Muscle Nerve.

On OnCo: Small intestine cancer

Paper: BCLXL blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer.

2026-09-21T00:00:00Z

Published in Signal Transduct Target Ther on 21 September 2026; matched the OnCo record for BIM.

21 September 2026, Signal Transduct Target Ther.

On OnCo: BIM

Paper: Carmofur inhibits ovarian cancer cell proliferation, migration, and invasion via disrupting the YAP-1/TEAD pathway: in vitro and in silico approaches.

2026-09-21T00:00:00Z

Published in 3 Biotech on 21 September 2026; matched the OnCo record for YAP1.

21 September 2026, 3 Biotech.

On OnCo: YAP1

Paper: CD36 links fatty acid metabolism to tumor immune microenvironment remodeling in breast cancer.

2026-09-21T00:00:00Z

Published in Transl Oncol on 21 September 2026; matched the OnCo record for FGA.

21 September 2026, Transl Oncol.

On OnCo: FGA

Paper: Chemotherapy-Free Polatuzumab Vedotin and Rituximab (Pola-R) for Frail, Older Patients with Relapsed DLBCL: A Case for Geriatric Assessment and Shared Decision-Making.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched Rituximab, Polatuzumab vedotin and Cytotoxic chemotherapy.

21 September 2026.

On OnCo: Rituximab, Polatuzumab vedotin, Cytotoxic chemotherapy, Geriatric assessment

Paper: Clinical Features, Treatment, and Outcomes of Sintilimab-induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

2026-09-21T00:00:00Z

Published in J Immunother on 21 September 2026; matched the OnCo record for Human normal immunoglobulin.

21 September 2026, J Immunother.

On OnCo: Human normal immunoglobulin

Paper: Code-multiplexed multi-frequency impedance cytometry with a unified deep-unfolding network.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.

21 September 2026.

On OnCo: Single-cell & spatial profiling

Paper: Combination pharmacotherapy for MASH: Potential synergistic approaches.

2026-09-21T00:00:00Z

Published in Biochem Pharmacol on 21 September 2026; matched the OnCo record for THRB.

21 September 2026, Biochem Pharmacol.

On OnCo: THRB

Paper: Comparative Effectiveness of Antibiotic Prophylaxis Regimens in Pediatric Acute Myeloid Leukemia.

2026-09-21T00:00:00Z

Published in Pediatr Blood Cancer on 21 September 2026; matched the OnCo record for Acute myeloid leukaemia in children.

21 September 2026, Pediatr Blood Cancer.

On OnCo: Acute myeloid leukaemia in children

Paper: Correction: Degradation of LMO2 in T cell leukaemia results in collateral breakdown of transcription complex partners and causes LMO2-dependent apoptosis.

2026-09-21T00:00:00Z

Published in Elife on 21 September 2026; matched the OnCo record for LMO2.

21 September 2026, Elife.

On OnCo: LMO2

Paper: Deciphering the apoptotic properties of ergolide, a sesquiterpene lactone form Inula oculus-christi, in hepatocellular carcinoma.

2026-09-21T00:00:00Z

Published in Cytotechnology on 21 September 2026; matched the OnCo record for CASP8.

21 September 2026, Cytotechnology.

On OnCo: CASP8

Paper: Deletion of a distal IRF4 element prevents inflammation-induced reprogramming of human regulatory T cell fate.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and IRF4.

21 September 2026.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling, IRF4, JUN, FOS, FOSB

Paper: Discrepancies in low-value practices across cardiovascular disease prevention guidelines. A narrative review.

2026-09-21T00:00:00Z

Published in Eur J Gen Pract on 21 September 2026; matched the OnCo record for LPA.

21 September 2026, Eur J Gen Pract.

On OnCo: LPA

Paper: Disease-state-themed escape room simulations in undergraduate pharmacy education: A systematic review.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched MET, Med-Gemini and MedLM and State.

21 September 2026.

On OnCo: MET, Med-Gemini and MedLM, State

Paper: Effects of Infrared and Dual-Wavelength Photobiomodulation Therapy on Mandibular Bone Healing Following Radiotherapy and Tooth Extraction: An Experimental Study.

2026-09-21T00:00:00Z

Published in J Oral Pathol Med on 21 September 2026; matched the OnCo record for BMP2.

21 September 2026, J Oral Pathol Med.

On OnCo: BMP2

Paper: Endothelial Plasticity as a Continuum in the Tumor Microenvironment.

2026-09-21T00:00:00Z

Published in Vasc Biol on 21 September 2026; matched the OnCo record for TEC.

21 September 2026, Vasc Biol.

On OnCo: TEC

Paper: ER-Localized Deadenylase PNLDC1 Suppresses Colorectal Cancer Progression by Targeting the mRNA Decay of TUBB4B.

2026-09-21T00:00:00Z

Published in Exploration (Beijing) on 21 September 2026; matched the OnCo record for Mebendazole.

21 September 2026, Exploration (Beijing).

On OnCo: Mebendazole, TUBB4B

Paper: Excessive activation of the RAS/MAPK pathway triggers adult-onset motor axonal degeneration.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched Mirdametinib and MEK1/2.

21 September 2026.

On OnCo: Mirdametinib, MEK1/2

Paper: Exercise and Intestinal Barrier Integrity: Molecular Mechanisms and Therapeutic Potential in Gut Health and Disease.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched NFE2L2.

21 September 2026.

On OnCo: NFE2L2

Paper: Genome-wide DNA methylation landscapes in gallbladder carcinoma: revealing shared and distinct epigenetic signatures across subtypes.

2026-09-21T00:00:00Z

Published in Epigenomics on 21 September 2026; matched the OnCo record for Papillary carcinoma of the gallbladder.

21 September 2026, Epigenomics.

On OnCo: Papillary carcinoma of the gallbladder

Paper: Genome-wide identification of MtTCTPs and functional analysis of MtTCTP3 as a positive regulator of nodulation in Medicago truncatula.

2026-09-21T00:00:00Z

Published in Plant Physiol Biochem on 21 September 2026; matched the OnCo record for TPT1.

21 September 2026, Plant Physiol Biochem.

On OnCo: TPT1

Paper: GMPS drives pancreatic cancer progression via suppressing DNA damage, STING activation and cellular senescence.

2026-09-21T00:00:00Z

Published in Transl Oncol on 21 September 2026; matched the OnCo record for GMPS.

21 September 2026, Transl Oncol.

On OnCo: GMPS

Paper: HSP90 shields ROC1/RBX1 from proteasomal degradation by CHIP E3 ubiquitin ligase to promote lung adenocarcinoma.

2026-09-21T00:00:00Z

Published in Signal Transduct Target Ther on 21 September 2026; matched the OnCo record for RBX1.

21 September 2026, Signal Transduct Target Ther.

On OnCo: RBX1, RIT1

Paper: IL-21 boosts T cell-therapy efficacy for solid tumors by enhancing mitochondrial Ca2+-mediated motility of effector CD8+ T cells.

2026-09-21T00:00:00Z

Published in Cancer Immunol Res on 21 September 2026; matched the OnCo record for TCR-T cell therapy.

21 September 2026, Cancer Immunol Res.

On OnCo: TCR-T cell therapy

Paper: Inducing oxidative stress by targeting the cholesterol biosynthesis pathway augments the efficacy of bortezomib in multiple myeloma.

2026-09-21T00:00:00Z

Published in Free Radic Biol Med on 21 September 2026; matched the OnCo record for FOXO3.

21 September 2026, Free Radic Biol Med.

On OnCo: FOXO3

Paper: Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation.

2026-09-21T00:00:00Z

Published in Signal Transduct Target Ther on 21 September 2026; matched the OnCo record for Aumolertinib.

21 September 2026, Signal Transduct Target Ther.

On OnCo: Aumolertinib

Paper: Integrative Genetic and Bioinformatic Analysis of Androgen Pathway Gene Polymorphisms, Testosterone, and PSA Levels in Prostate Cancer.

2026-09-21T00:00:00Z

Published in Genet Test Mol Biomarkers on 21 September 2026; matched the OnCo record for CYP17A1.

21 September 2026, Genet Test Mol Biomarkers.

On OnCo: CYP17A1, 5-alpha-reductase type 2

Paper: Intermolecular Hydrogen Bonds Inducing Paramagnetism for Nondestructive CEST Imaging of Nitric Oxide.

2026-09-21T00:00:00Z

Published in Adv Mater on 21 September 2026; matched the OnCo record for CCND2.

21 September 2026, Adv Mater.

On OnCo: CCND2

Paper: Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy.

2026-09-21T00:00:00Z

Published in J Thorac Oncol on 21 September 2026; matched the OnCo record for LTB.

21 September 2026, J Thorac Oncol.

On OnCo: LTB

Paper: Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Cancer.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling and Single-cell & spatial profiling.

21 September 2026.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling

Paper: Macrophages promote collagen deposition through circadian regulation of fibroblasts.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics and PDGFRA.

21 September 2026.

On OnCo: Proteomics & phosphoproteomics, PDGFRA

Paper: MATR3 is essential for oocyte growth and maturation quality through a dual molecular mechanism.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched KDM3B.

21 September 2026.

On OnCo: KDM3B

Paper: Methodological considerations in defining CBL as a prognostic biomarker in stage II melanoma.

2026-09-21T00:00:00Z

Published in Br J Cancer on 21 September 2026; matched the OnCo record for CBL.

21 September 2026, Br J Cancer.

On OnCo: CBL

Paper: Multi-omics integration identifies prognostic genes linked to adaptive immunity response and radiosensitivity in cervical cancer.

2026-09-21T00:00:00Z

Published in Transl Oncol on 21 September 2026; matched the OnCo record for TCL1A.

21 September 2026, Transl Oncol.

On OnCo: TCL1A

Paper: Multifaceted biological activities of linalool: antimicrobial, antibiofilm, cytotoxic, antiproliferative and caspase-3/7 activity.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched PSMA7.

21 September 2026.

On OnCo: PSMA7

Paper: Nutrigenomics and Epigenetic Regulation in Cancer Prevention: Molecular Mechanisms, Dietary Bioactives, and Translational Perspectives.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched DNA methylation profiling, Chemoprevention & risk-reducing surgery and Histone deacetylases.

21 September 2026.

On OnCo: DNA methylation profiling, Chemoprevention & risk-reducing surgery, Histone deacetylases

Paper: Otoprotective effect of MnTBAP in cisplatin-induced hearing loss.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched Sodium thiosulfate.

21 September 2026.

On OnCo: Sodium thiosulfate

Paper: Phase 1 study of KHK2455, a long-acting, potent and selective IDO1 inhibitor, in combination with avelumab in patients with locally advanced or metastatic urothelial carcinoma.

2026-09-21T00:00:00Z

Published in J Immunother Cancer on 21 September 2026; matched the OnCo record for CCND2.

21 September 2026, J Immunother Cancer.

On OnCo: CCND2

Paper: Radiomics and machine learning for differentiating pediatric intramedullary spinal tumors: a pilot study.

2026-09-21T00:00:00Z

Published in Eur Radiol Exp on 21 September 2026; matched the OnCo record for ITK.

21 September 2026, Eur Radiol Exp.

On OnCo: ITK

Paper: Real-world effectiveness and safety of secukinumab in giant cell arteritis: an Italian multicentre cohort study.

2026-09-21T00:00:00Z

Published in Arthritis Care Res (Hoboken) on 21 September 2026; matched the OnCo record for Tocilizumab.

21 September 2026, Arthritis Care Res (Hoboken).

On OnCo: Tocilizumab

Paper: Ribonucleotides Amplify Mitochondrial DNA-Driven cGAS-STING Activation via FdUMP-ribonucleotide Hybrid Particles to Potentiate Chemoimmunotherapy.

2026-09-21T00:00:00Z

Published in Adv Sci (Weinh) on 21 September 2026; matched the OnCo record for Floxuridine.

21 September 2026, Adv Sci (Weinh).

On OnCo: Floxuridine, TYMP

Paper: Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study.

2026-09-21T00:00:00Z

Published in Clin Cancer Res on 21 September 2026; matched the OnCo record for Adavosertib.

21 September 2026, Clin Cancer Res.

On OnCo: Adavosertib, Ceralasertib, WEE1

Paper: SMARCB1 (INI1)-Deficient Undifferentiated Rectal Carcinoma Mimicking Sarcoma: A Case Report and Literature Review.

2026-09-21T00:00:00Z

Published in Clin Case Rep on 21 September 2026; matched the OnCo record for Renal medullary carcinoma.

21 September 2026, Clin Case Rep.

On OnCo: Renal medullary carcinoma, SMARCB1

Paper: Sustained response (ORR4) as an on-treatment prognostic marker in mogamulizumab-treated mycosis fungoides and Sézary syndrome: the FIL-MOGA study.

2026-09-21T00:00:00Z

Published in Br J Dermatol on 21 September 2026; matched the OnCo record for Mogamulizumab.

21 September 2026, Br J Dermatol.

On OnCo: Mogamulizumab

Paper: SVPG: a pangenome-based structural variant detection approach and rapid augmentation of pangenome graphs with new samples.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched Long-read sequencing and State.

21 September 2026.

On OnCo: Long-read sequencing, State

Paper: Targeting CAF-induced oxidative phosphorylation in Dll4+ leader cells with injectable BZA-loaded MPDA hydrogel suppresses collective invasion in salivary adenoid cystic carcinoma.

2026-09-21T00:00:00Z

Published in J Mater Chem B on 21 September 2026; matched the OnCo record for DLL4.

21 September 2026, J Mater Chem B.

On OnCo: DLL4, IL6ST

Paper: Targeting the YAP-BST2 Axis Overcomes Intrinsic Anti-PD-1 Resistance in Metastatic Gastric Cancer.

2026-09-21T00:00:00Z

Published in Adv Sci (Weinh) on 21 September 2026; matched the OnCo record for ATP4B.

21 September 2026, Adv Sci (Weinh).

On OnCo: ATP4B

Paper: The Implementation of NICE Severity Modifier in the Single Technology Appraisal of Mirvetuximab Soravtansine: External Assessment Group Perspective.

2026-09-21T00:00:00Z

Published in Value Health on 21 September 2026; matched the OnCo record for KCNH1.

21 September 2026, Value Health.

On OnCo: KCNH1

Paper: The Situation and Factors Associated with Dental Caries Among Preschool Children in Nakhon Si Thammarat Province, Thailand.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched Azacitidine and Decitabine + cedazuridine.

21 September 2026.

On OnCo: Azacitidine, Decitabine + cedazuridine

Paper: Toripalimab Plus TPF as Induction Chemoimmunotherapy for the Treatment of Locally Advanced Hypopharyngeal Carcinoma: A Prospective Phase II Study.

2026-09-21T00:00:00Z

Published in Head Neck on 21 September 2026; matched the OnCo record for Toripalimab.

21 September 2026, Head Neck.

On OnCo: Toripalimab

Paper: Translation, cross-cultural adaptation of longitudinal curriculum objectives in sexual health to Brazilian medical education.

2026-09-21T00:00:00Z

Published in Sex Med on 21 September 2026; matched the OnCo record for NR4A3.

21 September 2026, Sex Med.

On OnCo: NR4A3

Paper: Treatment approaches to macrophage activation syndrome in real life and priorities for future research: results from the international METAPHOR project.

2026-09-21T00:00:00Z

Published in Arthritis Rheumatol on 21 September 2026; matched the OnCo record for Emapalumab.

21 September 2026, Arthritis Rheumatol.

On OnCo: Emapalumab

Paper: Treatment Strategies for Advanced Cutaneous Squamous Cell Carcinoma Following Anti-PD-1 Immunotherapy Failure: A Systematic Review of the Literature and Ongoing Trials.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched Oncolytic viruses, EGFR and PD-1.

21 September 2026.

On OnCo: Oncolytic viruses, EGFR, PD-1, Ipilimumab, EGF

Paper: Virotherapy for Spinal and Spinal Cord Tumors: Current Evidence and Future Perspectives.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched Oncolytic viruses.

21 September 2026.

On OnCo: Oncolytic viruses

Paper: What happens next: unexpected malignancies after extracapsular dissection of parotid tumors.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched MET and CCDC6.

21 September 2026.

On OnCo: MET, CCDC6

Paper: Why Some People Live Past 100: The Role of the Immune System in Centenarians, Semi-Supercentenarians and Supercentenarians.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.

21 September 2026.

On OnCo: Single-cell & spatial profiling

Paper: Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial.

2026-09-14T00:00:00Z

Published in Nat Cancer on 14 September 2026; matched the OnCo record for FOLFIRI.

14 September 2026, Nat Cancer.

On OnCo: FOLFIRI

Paper: Copper ion-induced MYH9 polymerization executes cuproptosis.

2026-09-14T00:00:00Z

Published in Cell on 14 September 2026; matched the OnCo record for MYH9.

14 September 2026, Cell.

On OnCo: MYH9

Paper: P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape.

2026-09-14T00:00:00Z

Published in J Clin Oncol on 14 September 2026; matched the OnCo record for Afatinib.

14 September 2026, J Clin Oncol.

On OnCo: Afatinib, Amivantamab, Sunvozertinib, Zipalertinib

Paper: Programmed ribosomal frameshifting triggers translational stress to promote viral replication.

2026-09-14T00:00:00Z

Published in Cell on 14 September 2026; matched the OnCo record for NDRG1.

14 September 2026, Cell.

On OnCo: NDRG1

Paper: Advancing neurofibromatosis research: a comparative review of animal models and their utility in dissecting the tumor microenvironment.

2026-09-20T00:00:00Z

Published in Lab Anim Res on 20 September 2026; matched the OnCo record for Genetically engineered mouse models.

20 September 2026, Lab Anim Res.

On OnCo: Genetically engineered mouse models

Paper: Beyond the blood-brain barrier: humanised mice, the missing link in glioblastoma research.

2026-09-20T00:00:00Z

Published in Oncogene on 20 September 2026; matched the OnCo record for Humanised mouse models.

20 September 2026, Oncogene.

On OnCo: Humanised mouse models

Paper: Bone Aging and Glycative Stress: Convergent and Divergent Mechanisms Driving Skeletal Deterioration.

2026-09-20T00:00:00Z

Published on 20 September 2026 after first appearing as a preprint; matched Senolytics after cancer treatment and RANK ligand.

20 September 2026.

On OnCo: Senolytics after cancer treatment, RANK ligand

Paper: Bridging the data latency gap: automated extraction of genomic biomarkers from unstructured clinical documents to support real-world oncology data.

2026-09-20T00:00:00Z

Published in Cancer Causes Control on 20 September 2026; matched the OnCo record for Oncotype DX.

20 September 2026, Cancer Causes Control.

On OnCo: Oncotype DX

Paper: Current Management and Investigational Therapeutic Strategies in Penile Squamous Cell Carcinoma: A Narrative Review.

2026-09-20T00:00:00Z

Published in Crit Rev Oncol Hematol on 20 September 2026; matched the OnCo record for Penile cancer.

20 September 2026, Crit Rev Oncol Hematol.

On OnCo: Penile cancer

Paper: Dynamic ctDNA Monitoring Predicts Recurrence and Guides Therapy in Postoperative Hepatocellular Carcinoma.

2026-09-20T00:00:00Z

Published in J Surg Oncol on 20 September 2026; matched the OnCo record for ASXL1.

20 September 2026, J Surg Oncol.

On OnCo: ASXL1

Paper: Emerging Patterns of Kidney Cancer in Young Adults: Where Do We Stand? Emerging Patterns of Kidney Cancer in Young Adults: Where Do We Stand?

2026-09-20T00:00:00Z

Published in Crit Rev Oncol Hematol on 20 September 2026; matched the OnCo record for Belzutifan.

20 September 2026, Crit Rev Oncol Hematol.

On OnCo: Belzutifan, Renal medullary carcinoma

Paper: From Damage to Dysregulation: Reframing Oxidative Stress and Redox Homeostasis in Central Nervous System Disease.

2026-09-20T00:00:00Z

Published on 20 September 2026 after first appearing as a preprint; matched State and SET.

20 September 2026.

On OnCo: State, SET

Paper: Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity.

2026-09-20T00:00:00Z

Published in Cardiovasc Toxicol on 20 September 2026; matched the OnCo record for HER4.

20 September 2026, Cardiovasc Toxicol.

On OnCo: HER4, NRG1, Strain echocardiography, TOP2B

Paper: Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups.

2026-09-20T00:00:00Z

Published in Br J Haematol on 20 September 2026; matched the OnCo record for Acute lymphoblastic leukaemia.

20 September 2026, Br J Haematol.

On OnCo: Acute lymphoblastic leukaemia

Paper: Leukemic Stem Cell-Targeted Liposomal Nanoimmunotherapy Reverses Immune Evasion and Inhibits Fusion Oncoprotein-Driven Acute Myeloid Leukemia by Silencing B-Cell Lymphoma 2.

2026-09-20T00:00:00Z

Published in Acta Biomater on 20 September 2026; matched the OnCo record for CD123.

20 September 2026, Acta Biomater.

On OnCo: CD123, MLLT3

Paper: Longitudinal Associations of Oxaliplatin Treatment With Chemotherapy-Induced Peripheral Neuropathy in Colorectal cancer Survivors up to 2 Years Post-Treatment.

2026-09-20T00:00:00Z

Published in Int J Cancer on 20 September 2026; matched the OnCo record for CAPOX.

20 September 2026, Int J Cancer.

On OnCo: CAPOX

Paper: Low-Concentration Enhancement Effect: Enabling Sensitive Detection of EML4-ALK Variants via Multiplex RT-MIRA.

2026-09-20T00:00:00Z

Published in J Clin Lab Anal on 20 September 2026; matched the OnCo record for EML4.

20 September 2026, J Clin Lab Anal.

On OnCo: EML4

Paper: Predictors of perceived value of multi-cancer early detection testing: a national PRECEDE-PROCEED framework study.

2026-09-20T00:00:00Z

Published in Cancer Causes Control on 20 September 2026; matched the OnCo record for Multi-cancer early detection.

20 September 2026, Cancer Causes Control.

On OnCo: Multi-cancer early detection

Paper: Probe-Based Confocal Laser Endomicroscopy During Immune Checkpoint Inhibitor Therapy: A Translational Framework Linking Intestinal Barrier Function, Microbiota, and Clinical Outcomes.

2026-09-20T00:00:00Z

Published on 20 September 2026 after first appearing as a preprint; matched Immune checkpoint inhibitors.

20 September 2026.

On OnCo: Immune checkpoint inhibitors

Paper: Progress with FAK inhibitors in the patent literature (2020-present).

2026-09-20T00:00:00Z

Published in Expert Opin Ther Pat on 20 September 2026; matched the OnCo record for Avutometinib + defactinib.

20 September 2026, Expert Opin Ther Pat.

On OnCo: Avutometinib + defactinib

Paper: Simultaneous multi-pollutant removal from photovoltaic wastewater by aluminum-modified biochar-enhanced partial nitritation-anammox process.

2026-09-20T00:00:00Z

Published in Bioresour Technol on 20 September 2026; matched the OnCo record for Secretory carcinoma of the breast.

20 September 2026, Bioresour Technol.

On OnCo: Secretory carcinoma of the breast

Paper: The p53-Associated Regulation of ATF4 mRNA Expression Involves p21 and p130 in a Stress-Dependent Manner.

2026-09-20T00:00:00Z

Published on 20 September 2026 after first appearing as a preprint; matched CDKN1A.

20 September 2026.

On OnCo: CDKN1A

Paper: Translating avelumab maintenance into clinical practice: nationwide outcomes in Czech patients with advanced or metastatic urothelial carcinoma.

2026-09-20T00:00:00Z

Published in Future Oncol on 20 September 2026; matched the OnCo record for Avelumab.

20 September 2026, Future Oncol.

On OnCo: Avelumab

Paper: Updates to contemporary care of glioblastoma.

2026-09-20T00:00:00Z

Published in Clin Med (Lond) on 20 September 2026; matched the OnCo record for Tumour treating fields.

20 September 2026, Clin Med (Lond).

On OnCo: Tumour treating fields

Paper: Upstream regulatory mechanisms and clinical significance of IQGAP2 deficiency in affecting PI3K activity to drive cell proliferation.

2026-09-20T00:00:00Z

Published in Hum Cell on 20 September 2026; matched the OnCo record for AREG.

20 September 2026, Hum Cell.

On OnCo: AREG, EREG, IQGAP1

Paper: XIST Is a Key Modulator Associated With the Adhesome Network.

2026-09-19T00:00:00Z

Published on 19 September 2026 after first appearing as a preprint; matched Atlas.

19 September 2026.

On OnCo: Atlas

Paper: A pyridone-fused imidazo[1,2-a]pyridine hybrid binds to tubulin at the vinblastine site, depolymerizes microtubules and inhibits Cancer cell proliferation.

2026-09-19T00:00:00Z

Published in Bioorg Chem on 19 September 2026; matched the OnCo record for Vinblastine.

19 September 2026, Bioorg Chem.

On OnCo: Vinblastine

Paper: A systematic review of cancer risks associated with MITF variants.

2026-09-19T00:00:00Z

Published on 19 September 2026 after first appearing as a preprint; matched MITF.

19 September 2026.

On OnCo: MITF

Paper: Acute myeloid leukemia arising in treated chronic lymphocytic leukemia/small lymphocytic lymphoma: a challenge in analysis of lineage relationship.

2026-09-19T00:00:00Z

Published in J Hematop on 19 September 2026; matched the OnCo record for CD123.

19 September 2026, J Hematop.

On OnCo: CD123

Paper: ARID2 Loss Destabilizes PBAF and Drives Colorectal Cancer.

2026-09-19T00:00:00Z

Published in Mol Carcinog on 19 September 2026; matched the OnCo record for ARID1A.

19 September 2026, Mol Carcinog.

On OnCo: ARID1A, ARID1B, ARID2, BRD7, SMARCD1, STAT5, SMARCA4, PBRM1

Paper: Beyond Exons 19 and 21: mapping the clinical and molecular diversity of uncommon EGFR mutations in a Brazilian NSCLC cohort.

2026-09-19T00:00:00Z

Published in Cancer Treat Res Commun on 19 September 2026; matched the OnCo record for STK11.

19 September 2026, Cancer Treat Res Commun.

On OnCo: STK11

Paper: Beyond poly(ADP-ribose) polymerase inhibition: emerging therapeutic strategies for germline BRCA1/2-mutated and PALB2-mutated breast cancers.

2026-09-19T00:00:00Z

Published in Curr Opin Oncol on 19 September 2026; matched the OnCo record for POLQ.

19 September 2026, Curr Opin Oncol.

On OnCo: POLQ, Talazoparib, WEE1

Paper: Blood flow restricted exercise with and without transcutaneous spinal cord stimulation via telehealth in persons with tetraplegia. A protocol for randomized clinical trial.

2026-09-19T00:00:00Z

Published in Spinal Cord on 19 September 2026; matched the OnCo record for Basal-like 1 triple-negative breast cancer.

19 September 2026, Spinal Cord.

On OnCo: Basal-like 1 triple-negative breast cancer, Basal-like 2 triple-negative breast cancer

Paper: Clinicopathologic Characteristics of Somatic TP53 Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review.

2026-09-19T00:00:00Z

Published in EJHaem on 19 September 2026; matched the OnCo record for BCR::ABL1.

19 September 2026, EJHaem.

On OnCo: BCR::ABL1

Paper: CRISPR and Gene Editing Approaches in Prostate Cancer: Clinical Applications and Therapeutic Potential.

2026-09-19T00:00:00Z

Published in Crit Rev Oncol Hematol on 19 September 2026; matched the OnCo record for TMPRSS2.

19 September 2026, Crit Rev Oncol Hematol.

On OnCo: TMPRSS2

Paper: Development of CRISPR_SCD001, an Autologous Hematopoietic Stem Cell Gene Therapy for Sickle Cell Disease after CRISPR-Cas9 Mediated Correction.

2026-09-19T00:00:00Z

Published in Mol Ther on 19 September 2026; matched the OnCo record for HBB.

19 September 2026, Mol Ther.

On OnCo: HBB, Plerixafor

Paper: Distribution, socioeconomic inequalities and contributing factors of anaemia prevalence across wealth index among Indian adolescent girls: multivariate decomposition analysis of nationally representative survey.

2026-09-19T00:00:00Z

Published in BMJ Paediatr Open on 19 September 2026; matched the OnCo record for HB-200.

19 September 2026, BMJ Paediatr Open.

On OnCo: HB-200

Paper: Efficacy and safety of omitting the clinical target volume in limited-stage small cell lung cancer: a large-scale multicenter real-world study.

2026-09-19T00:00:00Z

Published in Radiother Oncol on 19 September 2026; matched the OnCo record for Limited-stage small-cell lung cancer.

19 September 2026, Radiother Oncol.

On OnCo: Limited-stage small-cell lung cancer

Paper: Elucidating the molecular nexus between dental developmental anomalies and chronic inflammatory diseases: A computational systems biology analysis of genomic sequence homology using matrix factorization.

2026-09-19T00:00:00Z

Published in Comput Biol Chem on 19 September 2026; matched the OnCo record for MERTK.

19 September 2026, Comput Biol Chem.

On OnCo: MERTK

Paper: Extracellular Vesicles and Their Role in Osteogenesis.

2026-09-19T00:00:00Z

Published on 19 September 2026 after first appearing as a preprint; matched Mesenchymal stromal cells for tissue damage.

19 September 2026.

On OnCo: Mesenchymal stromal cells for tissue damage

Paper: Five-year outcomes of partial breast proton beam therapy without lumpectomy for early-stage breast cancer: an interventional prospective study.

2026-09-19T00:00:00Z

Published on 19 September 2026 after first appearing as a preprint; matched MRI, Proton therapy and Estrogen receptor.

19 September 2026.

On OnCo: MRI, Proton therapy, Estrogen receptor, EGF

Paper: Gastrodin enhances the spleen immune function in erythroleukemia by regulating T-cell receptor signaling pathway.

2026-09-19T00:00:00Z

Published in Med Oncol on 19 September 2026; matched the OnCo record for ITK.

19 September 2026, Med Oncol.

On OnCo: ITK, LCK

Paper: Head-to-head comparison of [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study.

2026-09-19T00:00:00Z

Published in Eur J Nucl Med Mol Imaging on 19 September 2026; matched the OnCo record for Gallium-68 gozetotide.

19 September 2026, Eur J Nucl Med Mol Imaging.

On OnCo: Gallium-68 gozetotide

Paper: Hepatocellular Carcinoma With a Grade 3 Neuroendocrine Tumor Component: A Case Report.

2026-09-19T00:00:00Z

Published in Int J Surg Pathol on 19 September 2026; matched the OnCo record for Grade 3 well-differentiated neuroendocrine tumour.

19 September 2026, Int J Surg Pathol.

On OnCo: Grade 3 well-differentiated neuroendocrine tumour

Paper: Immunogenic cell death as a mechanism of synergy between sunitinib and 177Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors.

2026-09-19T00:00:00Z

Published in Cell Death Discov on 19 September 2026; matched the OnCo record for Lutetium-177 dotatate.

19 September 2026, Cell Death Discov.

On OnCo: Lutetium-177 dotatate, Pancreatic neuroendocrine tumours

Paper: In vivo CAR‑T cell therapy: mechanisms, clinical advances and optimization strategies.

2026-09-19T00:00:00Z

Published in Biochem Pharmacol on 19 September 2026; matched the OnCo record for In vivo CAR-T.

19 September 2026, Biochem Pharmacol.

On OnCo: In vivo CAR-T

Paper: Integrating immunophenotyping and morphology in the diagnosis of acute leukemia at the National Oncology Center, Sana'a, Yemen.

2026-09-19T00:00:00Z

Published in Libyan J Med on 19 September 2026; matched the OnCo record for Anal high-grade squamous intraepithelial lesions.

19 September 2026, Libyan J Med.

On OnCo: Anal high-grade squamous intraepithelial lesions, Burkitt lymphoma, CD19, CD7

Paper: Investigating the impact of margins on the management of oropharyngeal cancer treated with transoral robotic surgery: a survey of head and neck oncologists' treatment patterns.

2026-09-19T00:00:00Z

Published in Oral Oncol on 19 September 2026; matched the OnCo record for Transoral robotic surgery.

19 September 2026, Oral Oncol.

On OnCo: Transoral robotic surgery

Paper: IRF1-driven chromatin and transcriptional regulation determines the anti-tumor responses to all-trans retinoic acid across cancer types.

2026-09-19T00:00:00Z

Published in Biochem Pharmacol on 19 September 2026; matched the OnCo record for Acute promyelocytic leukaemia.

19 September 2026, Biochem Pharmacol.

On OnCo: Acute promyelocytic leukaemia, IRF1

Paper: Lenalidomide triggers ferroptosis in multiple myeloma by blocking the c-Maf/USP7 signaling pathway to induce the ubiquitination and degradation of FTH1.

2026-09-19T00:00:00Z

Published in Cell Signal on 19 September 2026; matched the OnCo record for MAF.

19 September 2026, Cell Signal.

On OnCo: MAF

Paper: MicroRNA-122 as a regulator and biomarker of liver disease.

2026-09-19T00:00:00Z

Published in J Mol Med (Berl) on 19 September 2026; matched the OnCo record for FOXO3.

19 September 2026, J Mol Med (Berl).

On OnCo: FOXO3

Paper: Neuregulin-1 as a Context-Dependent Regulator of Neuroinflammation and Neural Repair: Mechanisms, Disease Relevance, and Therapeutic Challenges.

2026-09-19T00:00:00Z

Published on 19 September 2026 after first appearing as a preprint; matched HER2, HER4 and NRG1.

19 September 2026.

On OnCo: HER2, HER4, NRG1, EGF

Paper: PAX9 activates autophagy through a transcription-dependent mechanism, promoting EGFR degradation to restrict cell survival in oral cancer.

2026-09-19T00:00:00Z

Published in Br J Cancer on 19 September 2026; matched the OnCo record for PAX9.

19 September 2026, Br J Cancer.

On OnCo: PAX9

Paper: Precision therapeutic strategies for advanced gastrointestinal stromal tumors.

2026-09-19T00:00:00Z

Published in Cancer Metastasis Rev on 19 September 2026; matched the OnCo record for Ripretinib.

19 September 2026, Cancer Metastasis Rev.

On OnCo: Ripretinib

Paper: Prognostic Associations of Molecular MRD and Genomic Features in ZNF384-Rearranged B-ALL Undergoing Allo-HSCT.

2026-09-19T00:00:00Z

Published in Transplant Cell Ther on 19 September 2026; matched the OnCo record for CD33.

19 September 2026, Transplant Cell Ther.

On OnCo: CD33, ETV6, IKZF1, TCF3

Paper: Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA.

2026-09-19T00:00:00Z

Published in Clin Drug Investig on 19 September 2026; matched the OnCo record for Bendamustine.

19 September 2026, Clin Drug Investig.

On OnCo: Bendamustine

Paper: Regulatory roles of G-quadruplexes and G-quadruplex-binding proteins across the enhancer and promoter of the HBV genome.

2026-09-19T00:00:00Z

Published in Virol J on 19 September 2026; matched the OnCo record for CNBP.

19 September 2026, Virol J.

On OnCo: CNBP

Paper: ROS-Activated SHP-1 Signaling Underlies Artesunate-Mediated Inhibition of EMT and STAT3-Driven Prostate Cancer Progression.

2026-09-19T00:00:00Z

Published in Arch Biochem Biophys on 19 September 2026; matched the OnCo record for PTPN6.

19 September 2026, Arch Biochem Biophys.

On OnCo: PTPN6

Paper: Salivary Duct Carcinoma With Rhabdoid and Signet-Ring Cell Features Mimicking Invasive Lobular Carcinoma of the Breast: A Case Report and Review of the Literature.

2026-09-19T00:00:00Z

Published in Int J Surg Pathol on 19 September 2026; matched the OnCo record for Invasive lobular carcinoma of the breast.

19 September 2026, Int J Surg Pathol.

On OnCo: Invasive lobular carcinoma of the breast, Salivary duct carcinoma

Paper: SOX17 and TRPS1 in Müllerian, Breast, and Mesothelial Tumors: Tissue-Based Specificity Profiles and Diagnostic Pitfalls in Malignant Serous Effusions.

2026-09-19T00:00:00Z

Published in Int J Surg Pathol on 19 September 2026; matched the OnCo record for SOX17.

19 September 2026, Int J Surg Pathol.

On OnCo: SOX17, TRPS1

Paper: Stepwise neutrophil-to-neuron targeting nanotherapy for mitochondrial protection and blood-brain barrier preservation in ischemic stroke.

2026-09-19T00:00:00Z

Published in J Control Release on 19 September 2026; matched the OnCo record for TET1.

19 September 2026, J Control Release.

On OnCo: TET1

Paper: Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes.

2026-09-19T00:00:00Z

Published in Int J Hematol on 19 September 2026; matched the OnCo record for Decitabine.

19 September 2026, Int J Hematol.

On OnCo: Decitabine, Quizartinib

Paper: Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

2026-09-19T00:00:00Z

Published in Target Oncol on 19 September 2026; matched the OnCo record for Tucatinib.

19 September 2026, Target Oncol.

On OnCo: Tucatinib

Paper: TAPESTRY study: impact of prior transurethral resection of the prostate on outcomes after robot-assisted radical prostatectomy: a propensity score-matched cohort study.

2026-09-19T00:00:00Z

Published on 19 September 2026 after first appearing as a preprint; matched KLK3.

19 September 2026.

On OnCo: KLK3

Paper: Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study.

2026-09-19T00:00:00Z

Published in Int J Clin Oncol on 19 September 2026; matched the OnCo record for Amrubicin.

19 September 2026, Int J Clin Oncol.

On OnCo: Amrubicin

Approval: Accelerated approval: Camizestrant (US)

2026-09-04T00:00:00Z

Accelerated approval (Etcamah) The confirmatory requirement was still open 0.0 years later, when the FDA's table was read.

4 September 2026, FDA.

On OnCo: Camizestrant, HR-positive / HER2-negative breast cancer, HR-positive metastatic breast cancer after CDK4/6 inhibitors, Estrogen receptor

Approval: FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer

2026-09-04T00:00:00Z

On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.

4 September 2026, FDA.

On OnCo: Camizestrant, Palbociclib, Abemaciclib, Ribociclib, Breast cancer, HR-positive / HER2-negative breast cancer

Withdrawal: Withdrawal: Adagrasib (US)

2026-09-01T00:00:00Z

Withdrawn: the indication came off the label 2.3 years after its accelerated approval.

1 September 2026, FDA.

On OnCo: Adagrasib, Non-small-cell lung cancer, Colorectal cancer, Pancreatic ductal adenocarcinoma, KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer

Approval: Approval: Daraxonrasib (US)

2026-08-26T00:00:00Z

NDA 220910 approved as Rasonque: adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

26 August 2026, FDA.

On OnCo: Daraxonrasib, Pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, KRAS G12C-mutant pancreatic ductal adenocarcinoma, Non-small-cell lung cancer, Colorectal cancer

Approval: FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma

2026-08-26T00:00:00Z

On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

26 August 2026, FDA.

On OnCo: Daraxonrasib, Pancreatic ductal adenocarcinoma, Adenocarcinoma of the urethra, Adenocarcinoma of the lung

Approval: FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma

2026-08-25T00:00:00Z

On August 25, 2026, the Food and Drug Administration approved zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals) in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra, BeOne Medicines USA, Inc.), as first-line treatment for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test, and in combination with fluoropyrimidine-, and platinum-containing chemotherapy, as first-line treatment for adults with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test.: dolutegravir.

25 August 2026, FDA.

On OnCo: Tislelizumab, Zanidatamab, Platinum + etoposide, Oesophageal and junctional adenocarcinoma, Adenocarcinoma of the urethra, Adenocarcinoma of the lung, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer, Hepatocellular carcinoma, Recurrent and metastatic nasopharyngeal carcinoma, Biliary tract cancer, Gallbladder cancer, Biliary tract cancer, HER2

Approval: FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

2026-08-13T00:00:00Z

On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

13 August 2026, FDA.

On OnCo: Dexamethasone, Daratumumab, Iberdomide, Multiple myeloma, Smouldering multiple myeloma, Newly diagnosed multiple myeloma, transplant-eligible, Newly diagnosed multiple myeloma, transplant-ineligible, Plasma cell leukaemia, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma, Hodgkin lymphoma

Approval: FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma

2026-08-06T00:00:00Z

On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

6 August 2026, FDA.

On OnCo: Vusolimogene oderparepvec, Nivolumab, Relatlimab + nivolumab, Melanoma, Non-small-cell lung cancer, Renal cell carcinoma, Hodgkin lymphoma, Colorectal cancer

Approval: Approval: ArteraAI Breast (US)

2026-07-31T00:00:00Z

FDA clearance: first digital-pathology-based risk stratification tool for early HR+/HER2- breast cancer.

31 July 2026, FDA.

On OnCo: ArteraAI Breast, HR-positive / HER2-negative breast cancer, Atezolizumab, Non-small-cell lung cancer, Small-cell lung cancer, Hepatocellular carcinoma, Advanced hepatocellular carcinoma, Bladder & urothelial cancer, Belantamab mafodotin, Multiple myeloma, Relapsed or refractory multiple myeloma, BCMA, Cemiplimab, Melanoma, PD-L1-high non-small-cell lung cancer without a driver mutation, Cutaneous squamous cell carcinoma, Advanced cutaneous squamous cell carcinoma, Durvalumab, Biliary tract cancer, Intrahepatic cholangiocarcinoma, Extrahepatic cholangiocarcinoma, Encorafenib, Colorectal cancer, BRAF V600E-mutant colorectal cancer, BRAF V600E-mutant non-small-cell lung cancer, Lutetium-177 vipivotide tetraxetan, Prostate cancer, Metastatic castration-resistant prostate cancer, Metastatic hormone-sensitive prostate cancer, PSMA, Nivolumab, Renal cell carcinoma, Hodgkin lymphoma, Optune / Optune Pax, Glioma & glioblastoma, Pancreatic ductal adenocarcinoma, Locally advanced unresectable pancreatic ductal adenocarcinoma, Mesothelioma, Pembrolizumab, Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma, Triple-negative breast cancer, Head and neck squamous cell carcinoma, Piflufolastat F-18 / Pylarify TruVu, Relacorilant, Ovarian cancer, Platinum-resistant ovarian cancer, Advanced and metastatic adrenocortical carcinoma, Revumenib, Acute myeloid leukaemia, Acute lymphoblastic leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Menin, Tarlatamab, Extensive-stage small-cell lung cancer, Limited-stage small-cell lung cancer, Lung cancer, DLL3, Teclistamab, CD3, Trastuzumab deruxtecan, HER2-positive breast cancer, Gastric & gastro-oesophageal junction cancer, HER2-positive gastric cancer, Vepdegestrant, HR-positive metastatic breast cancer after CDK4/6 inhibitors, Estrogen receptor, Vusolimogene oderparepvec, Advanced melanoma, Zenocutuzumab, KRAS wild-type pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, Zongertinib, HER2-mutant non-small-cell lung cancer, HER2

Approval: FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

2026-07-31T00:00:00Z

On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).

31 July 2026, FDA.

On OnCo: Lutetium-177 vipivotide tetraxetan, Metastatic hormone-sensitive prostate cancer, Prostate cancer

Approval: FDA approves zidesamtinib for ROS1 -positive non-small cell lung cancer

2026-07-22T00:00:00Z

On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).

22 July 2026, FDA.

On OnCo: Zidesamtinib, Lung cancer, Non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer

Withdrawal: Withdrawal: Tazemetostat (US)

2026-06-22T00:00:00Z

Withdrawn: the indication came off the label 6.4 years after its accelerated approval.

22 June 2026, FDA.

On OnCo: Tazemetostat, Follicular lymphoma, Sarcomas, EZH2

Withdrawal: Withdrawal: Tazemetostat (US)

2026-06-22T00:00:00Z

Withdrawn: the indication came off the label 6.0 years after its accelerated approval.

22 June 2026, FDA.

On OnCo: Tazemetostat, Follicular lymphoma, Sarcomas, EZH2

Withdrawal: Withdrawal: Selinexor (US)

2026-04-30T00:00:00Z

Withdrawn: the indication came off the label 5.9 years after its accelerated approval.

30 April 2026, FDA.

On OnCo: Selinexor, Endometrial cancer, Multiple myeloma, Diffuse large B-cell lymphoma, Relapsed or refractory multiple myeloma, TP53

Withdrawal: Withdrawal: Zelenectide pevedotin (US)

2026-03-01T00:00:00Z

Programme deprioritised after regulatory feedback on Duravelo-2 design.

March 2026, FDA.

On OnCo: Zelenectide pevedotin, Bladder & urothelial cancer, Nectin-4

Result: A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor: Phase 3 result

2026-01-01T00:00:00Z

For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State: Arm A: Lazertinib With Amivantamab SC-CF 206 micrograms per milliliters (mcg/ml) versus Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion 144 micrograms per milliliters (mcg/ml).

2026, ClinicalTrials.gov.

On OnCo: A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor, Lazertinib, Non-small-cell lung cancer, Small-cell lung cancer, EGFR-mutated non-small-cell lung cancer

Result: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair: Phase 3 result

2026-01-01T00:00:00Z

Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator: BRCA Subgroup: Placebo With Abiraterone Acetate Plus Prednisone 25.99 months, hazard ratio 0.515.

2026, ClinicalTrials.gov.

On OnCo: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair, Abiraterone acetate, Niraparib, Prednisone, Prostate cancer, Metastatic hormone-sensitive prostate cancer

Result: A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma: Phase 3 result

2026-01-01T00:00:00Z

Overall Survival (OS): Nofazinlimab + Lenvatinib 21.6 months versus Placebo + Lenvatinib 18.5 months.

2026, ClinicalTrials.gov.

On OnCo: A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma, Lenvatinib, Hepatocellular carcinoma, Advanced hepatocellular carcinoma

Result: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S: Phase 3 result

2026-01-01T00:00:00Z

Major Pathological Response (MPR) - IASLC Method: Osimertinib + Chemo 25.6 % versus Osimertinib 24.8 % versus Placebo + Chemo 1.7 %.

2026, ClinicalTrials.gov.

On OnCo: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S, Osimertinib, Cisplatin, Carboplatin, Pemetrexed, Non-small-cell lung cancer

Result: A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma: Phase 3 result

2026-01-01T00:00:00Z

Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale: Nivo + Rela FDC SC 4.141 ug/ml versus Nivo + Rela FDC IV 3.901 ug/ml.

2026, ClinicalTrials.gov.

On OnCo: A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma, Nivolumab, Relatlimab + nivolumab, Melanoma, Advanced melanoma

Result: A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance: Phase 3 result

2026-01-01T00:00:00Z

Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original Scale: Nivolumab SC 77.373 μg/ml versus Nivolumab IV 36.875 μg/ml versus Nivo SC Process C 75.504 μg/ml versus Nivo SC Process D 75.596 μg/ml.

2026, ClinicalTrials.gov.

On OnCo: A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance, Nivolumab, Renal cell carcinoma, Clear cell renal cell carcinoma

Result: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer: Phase 3 result

2026-01-01T00:00:00Z

Progression Free Survival (PFS): Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 8.4 months versus Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 4.4 months, hazard ratio 0.43.

2026, ClinicalTrials.gov.

On OnCo: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer, Osimertinib, Non-small-cell lung cancer, Small-cell lung cancer

Result: A Study to Investigate Tolerability and Efficacy of Asciminib: Phase 3 result

2026-01-01T00:00:00Z

Time to Discontinuation of Study Treatment Due to Adverse Event (TTDAE) (From Interim Analysis): Asciminib 16 participants versus Nilotinib 34 participants, hazard ratio 0.45.

2026, ClinicalTrials.gov.

On OnCo: A Study to Investigate Tolerability and Efficacy of Asciminib, Asciminib, Nilotinib, Chronic myeloid leukaemia, Chronic myeloid leukaemia, chronic phase

Result: ALTAIR: Phase 3 result

2026-01-01T00:00:00Z

Median disease-free survival 9.30 against 5.55 months (hazard ratio 0.79, p=0.107): primary endpoint not met.

2026, DOI.

On OnCo: ALTAIR, Trifluridine/tipiracil, Signatera, Colorectal cancer

Result: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomi: Phase 3 result

2026-01-01T00:00:00Z

Red Blood Cell-transfusion Independence (RBC-TI) ≥ 12 Weeks (RBC-TI 12): Treatment 23.08 % versus Control 13.33 %.

2026, ClinicalTrials.gov.

On OnCo: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomi, Luspatercept, Myeloproliferative neoplasms, Primary myelofibrosis

Result: BL-B01D1-307: Phase 3 result

2026-01-01T00:00:00Z

PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).

2026, onclive.com.

On OnCo: BL-B01D1-307, Izalontamab brengitecan, Triple-negative breast cancer

Result: Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC: Phase 3 result

2026-01-01T00:00:00Z

Overall survival 17.7 vs 18.0 months (HR 0.92, p 0.32) overall and 20.4 vs 20.4 months (HR 1.05) in PIK3CA/AKT1/PTEN-altered tumours; PFS 5.6 vs 5.1 months (HR 0.72).

2026, DOI.

On OnCo: Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC, Capivasertib, Paclitaxel / nab-paclitaxel, Triple-negative breast cancer, Metastatic triple-negative breast cancer

Result: CLARITY-Gastric 01: Phase 3 result

2026-01-01T00:00:00Z

Co-primary endpoints including OS met (July 2026); numbers pending.

2026, cancernetwork.com.

On OnCo: CLARITY-Gastric 01, Sonesitatug vedotin, Ramucirumab, Gastric & gastro-oesophageal junction cancer, Claudin 18.2

Result: DeLLphi-305: Phase 3 result

2026-01-01T00:00:00Z

Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not yet disclosed.

2026, amgen.com.

On OnCo: DeLLphi-305, Tarlatamab, Durvalumab, Small-cell lung cancer, Extensive-stage small-cell lung cancer, DLL3

Result: DREAM3R: Phase 3 result

2026-01-01T00:00:00Z

Stopped early; primary endpoint not met.

2026, ClinicalTrials.gov.

On OnCo: DREAM3R, Durvalumab, Pemetrexed, Mesothelioma

Withdrawal: EU withdrawal: Duvelisib

2026-01-01T00:00:00Z

Marketing authorisation withdrawn in the European Union in 2026: Authorised May 2021; marketing authorisation withdrawn at Secura Bio's request 16 Feb 2026 (commercial reasons).

2026, European Commission (EMA opinion).

On OnCo: Duvelisib, Chronic lymphocytic leukaemia, Peripheral T-cell lymphomas, PIK3CA / PI3K-alpha

Withdrawal: EU withdrawal: Cinacalcet

2025-01-01T00:00:00Z

Marketing authorisation withdrawn in the European Union in 2025: Mimpara: authorised 22 Oct 2004; marketing authorisation withdrawn 18 Dec 2025.

2025, European Commission (EMA opinion).

On OnCo: Cinacalcet, Parathyroid carcinoma

Withdrawal: EU withdrawal: Lifileucel

2025-01-01T00:00:00Z

Marketing authorisation withdrawn in the European Union in 2025: MAA withdrawn 22 Jul 2025 after CHMP signalled a negative opinion (response rate, deaths, manufacturing).

2025, European Commission (EMA opinion).

On OnCo: Lifileucel, Melanoma, Non-small-cell lung cancer, Advanced melanoma

Law: European Health Data Space Regulation (EU) 2025/327

2025-01-01T00:00:00Z

A 2025 EU regulation that gives patients electronic access to their health records across the Union and creates national bodies that can grant researchers, regulators and companies permission to use anonymised or pseudonymised health data, phased in over the rest of the decade.

2025, European Union, regulation.

On OnCo: European Health Data Space Regulation (EU) 2025/327, GDPR and health data, Oncology EHR and real-world data platforms, Real-world evidence